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Abstract
Asthma is a chronic lung disease triggered by genetic and environmental risk factors
of an individual or a population. Intricate interactions account for a heterogeneous
disease profile, and the challenge consist in finding new therapeutic strategies for
severe asthma patients, who respond poorly to glucocorticoids, as well as for mild to
moderate asthma patients, whose quality of life is considerably reduced by long-term
side effects. The aim of this study was to test two different compounds in a mouse
model of allergic asthma. Experimental models of acute and relapsing asthma were
used to determine the effect of these compounds. Selected key parameters of allergic
disease were analyzed.
Our results indicate that one of the drugs tested, Ba 679 BR, is highly effective in
preventing airway hyperresponsiveness, but had no effect on acute lung inflammation
and mucus production during the onset of allergic asthma. However, this compound
at a 1 mg/kg dose had a significant effect on immunological memory responses,
illustrated by a reduction of airway inflammation and in particular eosinophilia. The
second compound tested, MAM-06.301, was able to reduce mucus hypersecretion in
peripheral airways and parenchymal inflammation without altering the inflammatory
response in the airways, as measured in the bronchoalveolar lavage fluid.
Taken together, these data illustrate that both compounds modulate important
features of allergic asthma in experimental models. We would argue that the Ba 679
BR compound may be useful in the treatment of exacerbations of allergic asthma and
that MAM-06.301 may be effective as an adjuvant therapy for allergic asthma but it
is necessary to further investigate the usefulness of these compounds as potential
adjuvants and steroid-sparing therapeutics.

Zusammenfassung
Asthma ist eine chronische Erkrankung der Lunge, welche sich als Folge genetischer
und umweltbedingter Risikofaktoren entwickeln kann. Dieses Zusammenspiel führt
zu einem heterogenen Krankheitsbild, mit einer Reihe von Komplikationen. Da-
her besteht die bedeutende Herausforderung darin, neue Therapien zu entwickeln;
einerseits für Patienten mit schwerem Asthma, die Glukokortikoid-resistent sind,
andererseits für Patienten mit mildem und leichtgradigem Asthma, deren Lebens-
qualität durch therapeutische Langzeiteffekte wesentlich reduziert ist. Ziel dieser
Studie war es, Effekte von zwei verschiedenen Präparaten an einem Mausmodell für
allergisches Asthma zu untersuchen. Wir benutzten dafür experimentelle Modelle für
akutes und rezidivierendes Asthma. Dabei wurden essentielle Parameter allergischer
Entzündungen untersucht.
Unsere Ergebnisse sagen aus, dass eines der getesteten Medikamente, Ba 679 BR,
während der Krankheitsentstehung, vorbeugend gegen eine Hyperreaktivität der
Luftwege wirkt. Allerdings konnte eine Wirkung von Ba 679 BR weder auf die
Entzündung, noch auf die Schleimproduktion der Atemwege nachgewiesen werden.
Bei einer Dosis von 1 mg/kg, weist das Medikament jedoch einen signifikanten Effekt
auf die immunologische Gedächtnisantwort auf, gezeichnet durch eine Reduktion
der Atemwegentzündung, hier insbesondere der Eosinophilen. Das zweite getestete
Medikament, MAM-06.301, konnte erfolgreich sowohl die Schleimproduktion der
peripheren Lunge als auch die parenchymale Entzündung reduzieren. Die entzünd-
liche Antwort in den Luftwegen wurde nicht beeinflusst, wie aus der Analyse des
Bronchoalveolären Lavages hervorging.
Zusammengefasst zeigen diese Daten, dass beide Medikamente wichtige Krankheits-
symptome von allergischem Asthma in experimentellen Modellen modulieren. Wir
schließen daraus, dass Ba 679 BR möglicherweise in der Behandlung von Asthmaan-
fällen angewendet werden könnte, und dass MAM-06.301 sich als Zusatztherapie für
allergisches Asthma etablieren könnte. Weitere Untersuchungen werden notwendig
sein, um die potenzielle Zweckmässigkeit dieser zwei Präparate, als Zusatzmitteln
und Steroid-freie Therapeutika, zu erforschen.
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Chapter 1
Introduction
1.1 The socioeconomic impact of asthma
Asthma is a major global public health problem with increasing incidence and
prevalence118. According to the World Health Organization (WHO), 300 million
people from all ages and ethnic backgrounds suffer from asthma worldwide, a total
that is expected to rise to about 400 million over the next 15-20 years. Asthma is still
responsible for about one out of 250 deaths worldwide1;102 and 80% of asthma deaths
occur in low and lower-middle income countries (WHO). Worldwide, asthma accounts
for around 1% of all DALYs 1 lost worldwide, which reflects the high prevalence and
severity of the disease102.
No prevention or cure exist for asthma yet, but in most patients, asthma can be
controlled with existing therapies. However, 5-10% of the asthma cases can only be
poorly controlled and are associated with serious impairment of the patient’s quality
of life as well as considerable consequences for the health care system. In fact, these
patients account for more than 50% of the total health care costs associated with
asthma34, due to frequent emergency room visits and hospitalization (direct costs) as
well as related work and school absenteeism (indirect costs)1;9. Taken together, the
high socioeconomic burden of the disease relies to a large extent on the consequences
of uncontrolled illness course9, hence an important factor which drives the active
research on novel therapeutics for asthma.
1Generally, the impact of a disease in the society can be measured in terms of loss of disability-
adjusted life years (DALYs), where one DALY is one year of healthy life lost due to premature
death or disability.
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Nevertheless, apart from the necessity to better understand the mechanisms under-
lying asthma, there is also an urgent need to find new therapeutical approaches in
order to ameliorate the conditions of asthma patients with controlled asthma.
1.2 Medical definition and etiology of asthma
1.2.1 Definition and classification of asthma
Asthma is a chronic lung disease that is defined by its clinical, physiological and
pathological features. Clinically, patients have recurrent episodes of coughing, wheez-
ing, breathlessness and chest tightness, particularly at night or in the early morning,
suggesting a circadian rhythm of symptoms emergence90. Physiologically, asthma
is characterized by airway hyperresponsiveness (AHR) in response to a stimulus
that would be innocuous in healthy individuals, which leads to expiratory airflow
limitation caused by reversible airways obstruction. Airway obstruction in asthma
is the consequence of bronchoconstriction, bronchial edema and increased mucus
production. The dominant pathological feature is airway inflammation resulting
from the recruitment of inflammatory cells as well as many mediators, and associ-
ated with airway structural changes, called airway remodeling. Structural changes
include goblet cell hyperplasia, associated with increased mucus production in the
airways, airway smooth muscle hypertrophy and hyperplasia, along with subepithelial
fibrosis1.
The classification of symptoms severity is useful for the management of the disease,
e.g. for the decision about an adequate treatment, at the initial diagnosis of the
patient. Asthma is subdivided in four main categories: intermittent, mild persistent,
moderate persistent and severe persistent asthma. The attribution of patients to
a certain group is decided according to frequency of symptoms during day and at
night, airflow limitation quantified by FEV1 (Forced Expiratory Volume in 1 second)
expressed as a percentage of the Vital Capacity or PEV (Peak Expiratory Flow) and
lung function variability expressed by FEV1 or PEV variability.
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1.2.2 Etiology of asthma
The strongest risk factors for developing asthma result from complex interactions
between genetic predisposition and environment of an individual or a population46.
In a broader context, genetic predisposition to atopy 2 or AHR belong to the main
host factors. Thus, others like obesity46;94;128 and sex77;101 were found to influence
the expression of asthma. Several environmental factors such as indoor allergens
(e.g. house dust mites, furred animals, molds, yeasts, fungi), outdoor allergens
(e.g. pollens, molds...), tobacco smoke, chemical irritants, occupational sensitizers3,
air pollution30;31;73 and even food109 lead to allergic sensitization and are triggers
of asthma development in susceptible organisms. One of the most disputed area
concerns the influence of viral infections on the development of allergic asthma.
Whereas the “hygiene hypothesis” suggests that a lack of early childhood exposure to
infectious agents, symbiotic microorganisms (e.g. gut flora), and parasites increase
susceptibility to allergic diseases, including asthma, by modulating immune system
development5;40;81;135, it is at the same time evident that infections are classical
triggers of asthma exacerbations16;106;131;151. Taken all together, the incredible
complexity of asthma is the interplay of single genetic or environmental factors,
dependent or independent from each other, which accumulate and result in unique
patterns of etiology in patients or group of patients20. The etiology of asthma can
therefore not be precisely determined due to the striking heterogeneity among the
risk factors.
1.3 Aim
The objective of my work was to test the effectiveness of two compounds in an
experimental mouse model of allergic asthma. Despite the high-effective current
treatment available for most of the asthma patients, development of novel drugs
against asthma stays indispensable for different reasons. A treatment is fully effective,
only if the disease for which it has been indicated can be clearly diagnosed and if
patients adhere consequently to the dosage protocol. Asthma is a heterogeneous
2Atopy: the propensity of an individual to produce IgE antibodies in response to various environ-
mental antigens and to develop strong allergic responses
3Occupational asthma: term used when disease development is specially associated with the work
environment of the patient, e.g. “baker’s asthma”
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disease and the treatment needs to be adjusted to the patients’ need in a continuous
manner, in order to assure the best possible control and management of the disease.
This has led to the implementation of guidelines in the health system as reported by
the “Global Initiative for asthma” of 200715. A safe and easy strategy to ensure a
good compliance is the introduction of long-lasting drugs that can reduce the daily
intake frequency and thus augment adherence to the treatment and the time between
asthma exacerbations. An adequate treatment against asthma should involve the
control of its underlying inflammation processes, as well as the relief of bronchospasms.
First of all, it is necessary to present the key players in asthma mechanisms and
the current medication, to subsequently understand the problematic, the needs and
the challenges in therapy development. Finally, I will present the two compounds I
tested and emphasize their promising role in the contribution to a better control of
asthma by novel classes of drugs.
1.4 Pathological features of asthma
1.4.1 Airway inflammation in allergic asthma: inflammatory cells
and mediators
Airway inflammation in asthma involves several inflammatory cells and multiple
mediators that result in characteristical pathophysiological changes and is strongly
associated with AHR and symptoms27;136. The airway inflammation is persistent
even though symptoms are episodic, and the relationship between the severity of
the disease and the intensity of inflammation is not clearly established yet22;37. The
inflammatory processes start before the appearance of asthmatic symptoms with the
infiltration of a normally innocuous antigen (Ag) through the epithelium, as this
tissue represents the first defense barrier between environment and body. At the site
of inflammation, the inhaled allergens encounter antigen-presenting cells (APCs) -
dendritic cells (DCs) and macrophages - and mast cells.
DCs
Immature DCs are present in the epithelial of the respiratory tract and control the
lung environment. They capture encountered Ags by endocytosis and transport these
4
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to the draining lymph nodes. During their migration, DCs mature to become very
efficient at presenting Ag and stimulating naive T cells by constitutive expression of
costimulatory molecules and MHC class II molecule. Therefore, DCs are crucial in
sensitization to allergens, have the capacity to initiate primary immune responses
(priming) and new evidences suggest a role in maintenance of established inflam-
mation67;91. In the lung, DC subsets have the ability to induce different types of
immune responses. Thus, Ag presentation by myeloid DCs leads to Th2 sensitization
typical of allergic disease, whereas antigen presentation by plasmacytoid DCs serves
to dampen inflammation67;92. It has been also shown, that the lineage commitment
of naive CD4+ T cells into their functionally different subtypes (discussed later in
this section) is guided by activated toll-like receptors (TLRs) present on the surface
of DCs and polarized by inhaled antigens17;74.
Macrophages
Macrophages are efficient in phagocytosis of large Ags and are activated by CD4+ T
cells. They are derived from circulating monocytes, which migrate to the lungs in
response to chemoattractant signals.
Mast cells
Mast cells display the high-affinity FcRI receptors on their surface, which bind
the Fc portion of IgE antibodies (Abs). When Ags bind to IgE, cross-linking
of these Abs occur, thus activating mast cells to synthesize and release several
bronchoconstrictors, including histamine and the lipid mediators leukotriene C4,
leukotriene D4, leukotriene E4 and prostaglandin D2. Epithelial cells on the surface
of the airway express the stem-cell factor (SCF) or c-kit ligand) and contribute to
recruit mucosal mast cells which express the c-kit receptor on their surface. Mast
cells also release cytokines linked to allergic inflammation, including IL-4, IL-5 and
IL-13 and their presence in airway smooth muscle has been linked to AHR25.
T cells
In allergic and more specifically in asthmatic patients, the transcription factor GATA3
(GATA-binding protein 3) is activated in naive CD4+ T cells leading to a lineage
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commitment and differentiation into T helper 2 (Th2) type of CD4+ T cells. These
cells in turn secrete Th2-type cytokines. IL-4 and IL-13 drive on one hand the
IgE production in B cells, on the other hand the binding of IL-4 to its receptor
leads to the activation of transcription factor STAT6 which in turn regulates the
downstream signal for GATA3 activation and contributes therefore to sustain the
secretion of Th2 cytokines during inflammation. IL-5 is responsible for eosinophil
differentiation in the bone marrow and IL-9 attracts and drives the differentiation
of mast cells. IL-13 induces mucus hypersecretion and AHR. The transcription
factor Tbet is crucial for Th1 commitment and secretion of Th1 type cytokine
IFN-γ, but regulates Th2 cytokines by inhibiting the function of GATA3. The T cell
specific transcription factors NFAT (nuclear factor of activated T cells) also seems
to enhance the transcriptional activation of GATA3 by targeting the IL4 promoter.
The newly discovered IL-33 (member of IL-1 family of cytokines) appears to promote
Th2-cell differentiation by translocating to the nucleus and regulating transcription
by epigenetic mechanisms. By binding to the surface receptor ST2 of Th2 cells, IL-33
also acts as a chemoattractant of Th2 cells.
Regulatory T cells (Tregs), another subtype of CD4+ T cells, have a crucial role in
the maintenance of peripheral tolerance by exhibiting suppressive effects on other
CD4+ T cells. A subset of these cells is characterized by expression of CD25 and
transcription factor FOXP3 and is currently subject of numerous studies. They
may have a role in asthma by regulating Th2 cell function but the mechanisms
of regulation seem to vary among allergic airway diseases, leading to unsharp and
non-generalizable conclusions.
The Th17 subset of CD4+ T cells has been shown to have an important role
in inflammatory and autoimmune diseases134;143. Their generation involves IL-23
and IL-21, as well as the transcription factor RORγt and STAT3 and even if
its role in asthma remains unclear, interesting observations have been reported113.
Increased concentration of IL-17 (predominant cytokine produced by Th17) have been
reported in the sputum of asthmatic patients26, and IL-17 has been associated with
neutrophilic inflammation, playing a role in certain phenotypes of asthma99;106;132.
Like mentioned above, Th17 cells also produce IL-21, which acts as a positive
autoregulatory mechanism by stabilizing Th17 differentiation and as a negative
regulatory mechanism by inhibiting FOXP4 expression and thus Tregs development.
IL-22 is released as well and stimulates the production of the anti-inflammatory
cytokine IL-10.
6
1.4 Pathological features of asthma
It is also uncertain, which role play invariant natural killer T cells (iNKT cells)
in asthma. This new subset of T cells is CD1-restricted 4, presents characteristics
of both natural killer cells (NK cells) and conventional T cells and expresses an
invariant α-chain of their T cell receptor (TCR). A population of iNKT cells exhibits
a Th2-like phenotype as they secrete IL-4 and IL-13 and were shown to induce AHR
in a mouse model of asthma107;138.
CD8+ T cells are present in patients with more severe disease and irreversible airway
obstruction139.
B cells
The cytokines IL-4 and IL-13 induce B cells to undergo immunoglobulin isotype
class switching to produce allergen-specific IgE. The IgE antibodies can then bind
to its high-affinity Fc receptors (FcRI) expressed on the surface of mast cells and
basophils or to its low-affinity Fc receptors (FcRII) expressed by other inflammatory
cells, including B cells, macrophages and possibly eosinophils62.
Granulocytes
Eosinophils are present in increased numbers in the airways of most asthmatic
patients. During inflammation, epithelial cells release the chemokine ligand 11
(CCL11) also known as eotaxin-1, which stimulates eosinophil recruitment to the
lung through the chemokine receptor 3 (CCR3) expressed on their surface. IL-5
produced by Th2 cells is critical for differentiation of eosinophils and for sustaining
eosinophilic inflammation. The functional role of eosinophils in asthma is not
clear though, as its role in participation of AHR has been questioned after the
disappointing results obtained by blocking of IL-5, that did not reduce AHR but
only eosinophilic inflammation93. Eosinophils are suggested to have a role in airway
fibrosis and interestingly, their presence seems to be a good marker for prediction of
corticosteroid sensitivity.
Neutrophilic inflammation has been associated with a non-eosinophilic phenotype of
asthma seen in patients with severe asthma, but their role remains uncertain.
4CD1 loads glycolipids and not protein antigens.
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1.4.2 AHR
AHR is an important hallmark of asthma and is linked to inflammation and airway
remodeling. The contractibility of airways smooth muscle is increased and leads
to the typical airway narrowing and associated symptoms in response to special
trigger. Furthermore, sensory nerves may be sensitized by inflammation leading thus
to exaggerated bronchoconstriction.
1.4.3 Airway remodeling
The airways of asthmatic patients are characterized by the presence of inflammatory
cells, but also by structural changes including mucus metaplasia, smooth muscle
hyperplasia, subepithelial fibrosis and increased angiogenesis. Airway remodeling is
probably driven by mediators released as a consequence of chronic allergic inflam-
mation116. It is hypothesized that the origin of asthma lies in the epithelium and
not in primarily in inflammatory pathways. Susceptibility genes expressed by the
epithelial have been identified, decreasing the resistance of the airway to environmen-
tal stimuli75. Subepithelial fibrosis is present in all asthmatic patients even before
the appearance of symptoms and results from the deposition of collagen fibers and
proteoglycans under the basement membrane. The increased thickness of airway wall
is due to airway smooth muscle hypertrophy and hyperplasia driven by inflammatory
mediators, and accounts for changes in the mechanical properties of the airways.
It seems that angiogenesis further supports the thickening of the airways. Mucus
hypersecretion results from goblet cell metaplasia in the epithelium as well as from an
increased size of submucosal glands. In transgenic studies, it was demonstrated that
the cytokines IL-11 and IL-13 produce responses in the murine airway with features
similar to those in human asthmatic tissues. IL-11 caused airway fibrosis with the
enhanced accumulation of interstitial collagen, myocytes, and myofibroblasts. IL-13
caused goblet cells metaplasia, enhanced mucin gene expression, enhanced tissue
hyaluronic acid accumulation, and subepithelial fibrosis.
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1.5 Asthma medication
Medications to treat asthma can be classified as controllers and relievers. Controllers
are medications taken daily on a long-term basis to keep asthma under clinical
control through their anti-inflammatory effects. Relievers act quickly to reverse
bronchoconstriction and relieve its symptoms. They are meant to be applied when
needed, and an increasing use of relievers is an indication of disease worsening.
1.5.1 Current asthma treatments
Approaches to treat asthma target bronchoconstriction and airway inflammation,
which is best obtained with a combination therapy of glucocorticoids (budenoside
or fluticasone) with β2-adrenoceptor agonists (formoterol or salmeterol) in a single
inhaler. This is currently the most effective anti-asthmatic treatment available
and it controls asthma in about 90-95% of patients28; however, 5-10% have severe
disease that responds poorly1. The effectiveness of low to moderate doses of inhaled
glucocorticoids (GCs) is improved by combination with long-acting β2 -adrenoceptor
agonists (LABA) and is better than that obtained with higher doses of inhaled
GCs alone35;58. There is increasing evidence that these two compounds act in a
synergestic way, by reciprocal positive interactions, although the mechanims are not
fully understood. Long-term treatment with inhaled GCs reverses airflow obstruction,
reduces exacerbations and the need for hospitalization, improves quality of life and
may have contributed to decrease asthma-linked deaths. However, long-term use of
high-dose inhaled GCs is problematic as it has serious side effects, such as cataracts,
osteoporosis in elderly patients, and stunting of growth in children1. The combination
therapy enables therefore a safer treatment by the use of low to moderate dose of
GCs and is effective as both maintenance and reliever therapy.
A considerable number of mediators are involved in the complex inflammatory
processes occurring in asthma and antagonists against many of these have been
developed. Nevertheless, the often disappointing results indicate that inflammation
cannot be reduced by the blockade of too specific targets. However, the only mediator
antagonists used in asthma therapy are antileucotrienes (or leukotriene modifiers),
which either block cysteinyl-leucotriene (cys-LT) receptors (montelukast) or the
synthesis of leucotriene (zileuton)11;19. Introduced in the 1990’s, they were the first
new class of asthma therapy for over 30 years. Although cys-LT antagonists have
9
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some beneficial clinical effects in asthmatic patients, they have proved to be relatively
weak compared to inhaled GCs. However, they have been shown to be useful as an
add-on therapy to inhaled GCs with the advantage of oral administration without
significant side effects.
It is nevertheless important to note that the current therapies are not curative, as
asthma symptoms and inflammation recur after treatment discontinuation.
1.5.2 Therapeutic issues, need and challenges for the
development of novel therapeutics
The necessity for new therapies consists in two major unmet needs. The first is
an improved compliance in the mild-to-moderate asthma patients, which could be
achieved by the development of safe oral versions of conventional treatments or of new,
more efficacious treatments, ideally pointing towards a cure. The second are patients
with poor controlled severe asthma, which do not respond well to combination therapy,
often due to a GC insensitivity. It became urgent to understand the mechanisms
behind severe asthma in order to identify new targets for drug development and reduce
the uncontrolled asthma cases. Some research areas concentrate for the moment
on a strategy to reverse GC resistance in patient with severe asthma. Furthermore,
the therapeutic effects of GCs are often accompanied by severe and sometimes
irreversible side effects. For this reason, another aspect of research has for goal
development of synthetic GCs, which show reduced side-effects while maintaining
their anti-inflammatory properties126. There are more and more evidences, that the
heterogeneity observed in the response to treatment can be attributed to the existence
of different asthma phenotypes caused by different pattern of inflammation24;66;71;145.
Behind the challenges to face in resolving the therapeutic issues discussed here, is
the need to develop discriminatory handprints of distinct disease subtypes and to
adapt therapies to the heterogeneous and complex aspects of asthma1;2.
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1.5.3 Improvement of current therapies
New longer lasting bronchodilators
The best reliever therapies existing at the moment for preventing and reversing
bronchoconstriction in asthma are the LABA, salmeterol and formoterol, which
are effective for 12 hours and additionally increase the duration of action of GCs
when both are used in combination. Currently, longer-acting β2 agonists, the so
called ultra-LABA (ULABA), with a duration of action exceeding the 24 hours
are under clinical development and might be suitable for a once-daily dosing. The
major advantage of the combination of inhaled GCs with once-a-day, fast onset
β2 agonists, is believed to bring improvement in compliance, rather than a better
efficacy of the treatment itself103. Novel class of bronchodilators, such as vasoactive
intestinal peptides analogues and K+-channel openers, are less adapted due to their
vasodilators effect13.
New corticosteroids with reduced systemic side effects
The systemic side-effects of inhaled GCs are attributed to their absorption by the lung
and are greater with higher GC dose. Efforts are therefore made for the development
of safer GCs with low systemic bioavailability, high pulmonary deposition and
inactivation or clearance in the circulation. Ciclesonide for example, is a pro-drug
activated by lung-specific esterases, which seems to have less systemic effects than
currently available GCs. GCs affect gene expression by two mechanisms. The
anti-inflammatory effects are mainly mediated by inhibition of transcription factors
through a non-genomic effect called transrepression, while transactivation accounts
for many of the undesirable side effects and is mediated by genomic effects and
binding of GC receptors to DNA. An ensuing interesting approach is the development
of dissociated GCs, which are able to selectively activate the transrepression rather
than the transactivation mechanism through the GC receptor32;126 and are under
clinical development.
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1.5.4 Mediator antagonists
Beside leukotriene antagonists, inhibitors of pro-inflammatory mediators, like kinins,
platelet-activating factor, histamine and prostaglandins (PGs) have proved no ben-
eficial clinical effect against asthma. Efforts are made to find new targets among
lipid mediators, but progresses are slow, due to safety and efficacy concerns or to
discrepancy between results obtained in animal models and in humans.
Cytokine inhibitors and anti-inflammatory cytokines
There has been a lot of energy investigated in identifying cytokines as targets for new
asthma therapies, because of their key role in inflammation and airway remodeling.
The demonstration that inhibition of Th2-derived cytokines in many animal models
of asthma prevented all aspects of disease drove to the development of antagonists
and antibodies directed against IL-4 and IL-5. Deception was great, as these findings
could not be replicated in asthmatic patients. However, there is currently interest in
blocking IL-13, which is found in higher proportion than IL-4 in asthmatic airways150.
Other cytokine inhibitors found interest in actual research and I would like to mention
the most promising ones. Tumor necrosis factor-α (TNF-alpha) was found to have a
role in severe asthma and anti-TNF-α therapies (etanercept and infliximab) are in
clinical development. SCF is a key regulator of mast-cell survival in the airways and
acts through the c-kit receptor on mast cells. Promising results were obtained in
animal models by blockade of SCF or c-kit (imatinib). Thymic stromal lymphopoietin
(TSLP) is expressed on airway epithelial cells of asthmatic patients and through its
association with dendritic cells activation, became object of intense research in the
last years. It was even characterized as a master switch in allergic inflammation96
and offers new perspectives in therapeutic approach.
Although the use of anti-inflammatory cytokines like IL-10 and IL-12 offered attractive
therapeutic perspectives, results were rather disappointing with difficulties to replicate
positive effects in humans and undesirable side-effects13.
Chemokine and chemokine receptor antagonists
Recruitment of inflammatory cells into the airway is linked by chemokines, small
peptides indispensable in the development of asthma, which bind to their respective
12
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chemokine receptors. Currently, targeting CCR3 has been of major interest. It is
expressed on eosinophils, mast cells and some Th2 cells and its ligands are increased
in asthma and mediate eosinophil recruitment. Inhibitors of CCR3 were effective in
animal models39;144 and are undergoing clinical trials.
1.5.5 Novel anti-inflammatory treatments
Phosphodiesterase inhibitors
Phosphodiesterases (PDE) are found in a variety of inflammatory and structural cells
and are classified in 11 families. Most advanced research has been done on the PDE4
inhibitors, which specifically prevent the hydrolysis of cAMP, leading to inhibition
of inflammatory cells acting in asthma. Even if these inhibitors (roflumilast and
cilomilast) showed high efficacy in animal models, a major limitation in human ap-
plication is the unattractive side-effect profile, including nausea, vomiting, headaches
and gastrointestinal disturbance36. Finding inhibitors that would target specific
isoenzymes of PDE4, not mediating these side-effects, are now being considered.
Inhibition of transcription factors, kinases and adhesion molecules
The transcription factor nuclear factor-κB (NFκB) plays a key role in the regulation
of inflammatory genes involved in asthma pathogenesis as its activation is enhanced
in mild asthma and further increases in severe asthma. Interestingly it seems that
the NFκB pathway is implicated in GC-resistant asthma. Inhibitors of NFκB
undergo preclinical testing10. The p38 mitogen activated protein (MAP) kinase
activates inflammatory genes in asthmatic processes, and inhibition by an anti-sense
molecule was able to suppress pulmonary inflammation in a murine model48. As
these molecules play a role in a broad range of cell types and of mechanisms, there
are concerns about potential dangerous side-effects in humans so that inhalation
might be the preferred route of delivery. Among many of the adhesion molecules
having a role in asthma, the very late antigen-4 (VLA-4), involved in recruitment of
eosinophils and T cells, has been targeted with most success. Currently, inhibitors of
VLA-4 are tested in humans, but concerns raise about their long-term safety.
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Restoration of GC responsiveness
Data indicate that the GC-receptor mediated suppression of NFκB involves the
recruitment of the histone deacetylase-2 (HDAC-2) and that this enzyme activity
is decreased in GC-insensitive asthma12;82;85. It has been shown, that low-dose
theophylline exerts an anti-asthma effect through increasing activation of HDAC-
2, which is subsequently recruited by corticosteroids to suppress inflammatory
genes38;84.
Immunomodulation and anti-allergy treatments
There is growing evidence for the central role of IgE in airway inflammation and
asthma and the clinical effectiveness of blocking IgE with omalizumab, a recombinant
humanized monoclonal antibody directed to the high-affinity IgE receptor (FcRI)
binding domain of the human IgE. It is now approved for asthma therapy in some
countries, but present applicability issues10. As the implementation of such a therapy
is very cost effective, it can only be used for a small group of patients, with very severe
disease10. Additionally, the subcutaneous route of administration presents practical
hurdles for patients. However, omalizumab is successful and encourages to further
search for inhibitors of IgE-mediated signal transduction pathways. Lumiliximab, an
inhibitor of CD23, the low-affinity IgE receptor (FcRIII), is now being tested in
clinical trials.
1.6 Two novel compounds for the treatment of
asthma
1.6.1 Tiotropium Bromide (Spiriva, Ba 679 BR)
Drug properties
Tiotropium Bromide is a quaternary ammonium derivative and a structural analog
of atropine6. Tiotropium Bromide is a specific antagonist of muscarinic receptors,
which binds to all receptor subtypes with similar affinities, as indicated by similar
dissociation constants from the receptors (Kd of M1, M2 and M3 are between 0.01
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and 0.04). However, kinetic studies on the half-life of dissociation (t1/2) showed that
it dissociates very slowly from M1- and M3-receptors (t1/2 = 14.6 h vs 34.7 h) but
more rapidly from M2-receptors (t1/2 = 3.6h), thereby giving it a unique kinetic
selectivity6;43.
Figure 1.1 Structure of Tiotropium Bromide (C19H22NO4S2Br.H20)
Current indication
In January 2004, the orally inhaled long-acting anticholinergic bronchodilator Tio-
tropium Bromide, was approved by the US FDA for the once-daily maintenance
treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is
characterized by a progressive development of not fully reversible airflow limitation,
and represents one of the most common chronic diseases. COPD is largely caused by
smoking, although other factors exist, such as air pollution. Tiotropium demonstrates
a significantly longer duration of protection than an equipotent dose of its predecessor
ipratropium, most likely due to its slow dissociation from human M3-receptors43;69.
It is a quaternary ammonium derivative which results in little systemic absorption
following inhalation and thereby in little side-effects.
Since its introduction on the market, data support the use of tiotropium once-daily as
first-line maintenance treatment in patients with COPD141. Tiotropium is effective in
improving dyspnea, exacerbations and related hospitalizations, health-related quality
of life and lung function in patients. It exceeds the benefits seen with ipratropium141
or with LABA treatment (salmeterol)45. Moreover, anticholinergics are particularly
important bronchodilators in COPD, because the vagal tone appears to be the only
reversible component of airflow limitation in this disease122. Preliminary data suggest
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that combining Tiotropium with LABA may produce additional bronchodilator action
in COPD137;153. However, long-term studies are required to clarify Tiotropium’s role
in comparison to, or in combination with LABA and to assess its effectiveness in mild
and very severe COPD14. Though, Tiotropium treatment seems to be associated
with an increase in annual costs per patient, as calculated in two 1-year randomized,
double-blind clinical trials in the Netherlands and Belgium114.
COPD and asthma have different diagnostic criteria and treatment paradigms but
can occur in the same patient. In a recent study, the spirometric effects of Tiotropium
in COPD patients with concomitant asthma were investigated. Satisfying results
were obtained, as spirometric improvements along with symptomatic benefit were
achieved, as seen by reduced need for rescue medication100.
Promising facts for a beneficial effect on asthma
In the last two decades, anticholinergic agents have been generally regarded as the
first-choice bronchodilator therapy in the routine management of stable COPD, but
only to a lesser extent in asthma.
Acetylcholine (ACh) is the primary parasympathetic neurotransmitter in the air-
ways, associated with the induction of airway smooth muscle contraction and mucus
secretion. Parasympathetic activity is increased in airway inflammation, which is
the basis for the use of anticholinergic therapy in asthma and COPD60. Additionally
new evidences indicated that ACh, acting through muscarinic receptors, had an
essential regulatory role in allergen-induced airway smooth muscle remodeling59–61.
New insights in muscarinic ACh receptors (mAChR) signaling identified mAChR-
regulated pathways as potential novel targets for the treatment of various diseases,
notably asthma and COPD60;146. M1-receptors in parasympathetic ganglia facilitate
cholinergic neurotransmission and therefore enhance cholinergic bronchoconstriction,
whereas M3-receptors on airway smooth muscle cells and glands mediate bronchocon-
striction and mucus secretion. M2-receptors at cholinergic nerve endings inhibit the
release of ACh and therefore act as feedback inhibitory receptors (autoreceptors)6.
Studies investigated the effect of the anticholinergic drug glycopyrrolate in human
airways and compared it with ipratropium and later with Tiotropium. Tiotropium
treatment assured the longest bronchodilation duration63;68;140. Because of its selec-
tivity for the muscarinic M3-receptor, we assumed that Tiotropium protects against
bronchoconstriction and aberrant mucus production in asthma.
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1.6.2 Escin
Drug properties
The triterpene saponin escin is the active component of the extract of seeds of
the horse chestnut tree (Aesculus hippocastanum), used for its therapeutic proper-
ties98. The β but not the α molecular structure of escin is active and available in
pharmaceutical products133.
Figure 1.2 Structure of escin Ia (C59H86O24)
Escin owes its therapeutic application mostly to its anti-edematous, anti-inflammatory
and venotonic properties. A wide range of mechanisms underlying these effects is
currently known and will be discussed here.
The ability of escin to induce venous contraction is based on its permeabilizing
effect on smooth muscle cells. Increase in permeability leads to a higher membrane
sensitivity to calcium ions and finally to a calcium-induced, calmodulin-dependent,
contraction of these smooth muscles89. Furthermore, it has been shown that escin
makes the cell membrane mainly permeable to high-molecular weight molecules89.
The anti-exudative effect of escin has been associated with an increased production
of Fα-type PGs leading to vasoconstriction18;97.
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The anti-edematous effect of escin has been demonstrated in various studies. In
fact, in inflammatory conditions as well as during blood stasis resulting in decreased
oxygen supply, a reduction in ATP may occur. An ATP decrease results in a
cascade of metabolic events like release of PGs and PAF (platelet activating factor),
neutrophil recruitment, adherence and activation, all leading to venous stasis and
edema in the case of varicose disease133. A protective effect of escin on endothelial
cells was shown in in vitro models of hypoxia and inflammation. Escin was able
to inhibit important steps of the activation of endothelial cells caused by hypoxia,
including the decrease in ATP content, which is the starting point of the activation
cascade, and the increase in the activity of phospholipase A2, an enzyme responsible
for the release of precursors of inflammatory mediators. Escin could prevent the
increased neutrophil adherence occurring in hypoxia-activated endothelial cells3.
This effect was shown to be mediated by an inhibitory action on VCAM-1 (vascular
cell adhesion molecule 1) and PECAM-1 (platelet endothelial cell adhesion molecule
1), giving an additional protection on endothelial cell morphology. Additionally,
escin pre-treatment reduced IL-6 release from LPS-activated vascular endothelium110.
Furthermore, the endothelium-protectant effect of escin was confirmed as it was
found to be able to enhance the endothelium-dependent relaxation induced by ACh.
This effect was attributed to enhanced nitric oxide (NO) production by endothelial
NO synthase, a calcium-dependent enzyme, activated by the escin-induced increase
of endothelial cell calcium permeability29. NO, a potent vasodilator produced by
endothelial cells, is thought to be the endothelium-dependent relaxing factor (EDRF)
which mediates vascular relaxation in response to ACh, bradykinin and substance P in
many vascular beds. NO has been implicated in the regulation of blood pressure and
regional blood flow, affects vascular smooth-muscle proliferation and inhibits platelet
aggregation and leukocyte adhesion79. Taken together, escin reduces neutrophil
adherence and activation as well as the release of inflammatory mediators, resulting
in the protection of veins and reduction of edema133. In a study performed on a model
of traumatic brain injury in rats, escin could dramatically inhibit NF-κB activation
as well as the expression of TNF-α protein and alleviate rat brain edema108.
The anti-inflammatory action of escin is closely connected to its anti-edematous and
venotonic properties. It has been shown that escin could inhibit acute inflammation
and granuloma formation, cause acceleration of gastrointestinal transit, help recover
intestinal motility, and attenuate the formation of postoperative adhesions53. Further
studies shed light on possible mechanisms underlying an escin-mediated release of NO
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and PGs. An antagonist effect of escin on serotonin (5-HT)53;104 and histamine120
was supported by studies reporting an acceleration of gastrointestinal transit in mice.
Proposed mechanisms are the selective activation of 5-HT2 receptors, which in turn
causes the release of NO and PGs and the antagonism of the pro-inflammatory 5-HT1
receptor104. Escin’s anti-inflammatory properties have also been associated with
anti-hyaluronidase activity in tissue52. Hyaluronidase hydrolyzes glycosaminoglycans
(GAGs), including hyaluronan, in the extracellular matrix during tissue remodeling
and its activity increases in chronic inflammatory conditions23. Escin may contributes
consequently to shift the balance between synthesis and degradation of proteoglycans 5
towards net synthesis, strengthening the capillary wall and preventing from leakage133.
Anti-obesity effects of escin were also reported. In this context, an effect on escin on
pancreatic lipase activity, a fat-cleaving enzyme, was proposed78.
Interesting work has been published in the last two years, indicating possible inhibitory
effects of escin on mechanisms associated with cancer development. Thus, escin
inhibited colonic aberrant crypt foci formation in rats and regulated the cell cycle
growth by inducing p21(waf1/cip1) in in vitro cultured colon cancer cells. This novel
feature suggests escin as a potential useful candidate for colon cancer chemoprevention
and treatment117. Furthermore, a recent study claimed that escin was a potent natural
inhibitor of proliferation and inducer of apoptosis in human chronic myeloid leukemia
K562 cells in vitro, being thus a candidate to be considered for the exploration of
potential antileukemia drugs112. New findings declare an effect of escin on endothelial
cells proliferation, migration and apoptosis and indicate a potential anti-angiogenic
activity via its direct effects on endothelial cells142. According to the results of the
study, this effect would be mediated on one hand by an increased expression of
thrombospondin-1 (TSP-1), on the other hand by a decreased expression of PKC-αC
as well as a decreased activation of p44/42 MAPK (ERK) and p38 MAPK.
Current indication
Escin is currently indicated as a safe and effective treatment for chronic venous
insufficiency (CVI)42;119;120;133. It is used as well in the prevention of post-operative
edema, against hemorrhoids133 and a cosmetic use due to anti-aging properties have
also been reported55;148. Recently, escin combined with another compound, was
found to be successful for the treatment of inner ear perfusion disturbances130.
5Proteoglycans: also called mucopolysaccharides, are formed by linkage of GAGs to core proteins
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Promising facts for a beneficial effect on asthma
The anti-inflammatory and anti-edematous properties of escin make it an attractive
candidate for the treatment of allergic inflammation in asthmatic airways. Escin acts
on different targets of the inflammation process, that have been shown to have a
role in asthma. Escin was recently shown to inhibit NF-κB108, a transcription factor
with important role in the regulation of inflammatory genes involved in asthma
pathogenesis. In fact, in research fields aiming to find new targets for asthma therapy,
anti-NFκB molecules are currently being tested. Furthermore, the anti-hyaluronase
activity52 of escin might be of particular interest, as there is enhanced hyaluronic
acid accumulation in lung tissue of asthmatic patients51. It has been shown that
TNF-α and IL-1β, cytokines implicated in the pathophysiology of asthma64, were
potent enhancers of hyaluronidase expression and activity in human airway epithelial
cells and lung fibroblasts111;149. Additionally, as the lipid mediator PAF has been
associated with catabolic events occurring in varicose disease133 and key features of
asthma33;72, a putative inhibiting effect of MAM-06.301 on PAF might help reducing
airway edema, eosinophil accumulation in the airway wall and AHR. Taken together,
escin has beneficial effects on several aspects of inflammation pathways, thus being
a promising candidate for the reduction of airway inflammation and remodeling in
asthma.
1.7 Mouse model of experimental allergic asthma
The application of generalizable mouse models in the modeling of human diseases be-
came an indispensable tool in medical research41 and contributes to evident progress
in understanding pathological processes and developing treatment strategies50;129;152.
An innovative model of experimental allergic asthma has been established in our
laboratory consisting in using low-fat powder milk as a natural and clinically relevant
allergen for the sensitization of C57BL/6 mice. Whereas the latter showed consider-
able disease pattern, BALB/c mice turned out to be unresponsive for this protocol.
Milk generates an allergic response to a combination of proteins and mimics therefore
allergic asthma in patients with the significant advantage of being inexpensive. The
pathological picture obtained showed evidences of a Th2-driven allergen-induced
pulmonary inflammation and confirmed findings with other allergens, like ovalbumin
in BALB/c mice. The mouse model of allergic asthma shares many features with
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human asthma, including the development of eosinophilic inflammation in lung tissue
and in the bronchoalveolar lavage fluid, Ag-specific Ab response (IgG1 and IgE), and
the production of Th2 cytokines (IL-4)54;152. The remitting and relapsing process
induced by antigenic stimulation can be mimicked in a mouse model of experimental
allergic asthma and consequently be used advantageously to test the therapeutic
effects of the compounds at different stages of the disease.
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Materials and Methods
2.1 Experimental design of the in vivo model
2.1.1 Mice
C57BL/6 and BALB/c female mice were purchased from Charles River laboratories
and used when they were 6 to 8 weeks old. They were maintained in the facilities
of the pharmacology department and the veterinary medicine. OVA-free food and
water ad libitum were given to the mice. All experimental protocols were complied
with the requirements of the Austrian Ministry of Science.
2.1.2 Setup of experimental allergic asthma and treatment
protocol in the C57BL/6 mouse strain
Experimental approach for Tiotropium bromide (Ba 679 BR) treatment in
the acute model of experimental allergic asthma
Mice were sensitized and challenged with low-fat powder milk. They were immunized
10 µg milk in 200 µl 1x PBS intraperitoneally on days 0 and 21. The mice were
exposed to aerosolized milk solution dissolved in 1x PBS, produced by an ultrasonic
nebulizer, following three different protocols. Either twice a day for one hour with
2% milk solution on two consecutive days (days 28 and 29), twice a day for one
hour with 2% milk solution on a single day (day 29) or twice a day for 90 min with
1% milk solution on two consecutive days (days 28 and 29). The mice were treated
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either with Tiotropium Bromide (0.1 mg/kg, 1 mg/kg or 10 mg/kg in 50 µl or 25 µl
1x PBS) or with 1x PBS (vehicle control) by intranasal application of the compound
either once on the day before the aerosol challenge or five times once a day, between
day 25 and day 29. The mice were lethally anesthetized on day 31. There were four
groups of mice per experiment: naive mice as negative controls, PBS-treated mice as
vehicle controls and two groups of mice treated with two different concentrations of
Tiotropium Bromide.
Figure 2.1 Experimental setup - First experimental approach for acute asthma.
Figure 2.2 Experimental setup - Second experimental approach for acute asthma
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Figure 2.3 Experimental setup - Third experimental approach for acute asthma
Experimental approach for Tiotropium Bromide (Ba 679 BR) treatment in
the memory model of experimental allergic asthma
In the memory model of disease, acute disease was induced as mentioned above and
after a recovery phase of 113 days (~three and a half month), disease relapse was
induced by allergen challenge on two consecutive days with 1% milk solution (days
142 and 143) for 90 min. The mice were treated on five consecutive days between the
days 139 and 143 by intranasal instillation of the compound, either 1 mg/kg or 0.1
mg/kg, diluted in 25 µl 1xPBS. The vehicle group were administered 25 µl 1x PBS
only. Mice were lethally anesthetized 72h after the last treatment. There were four
groups of mice per experiment: naive mice as negative controls, PBS-treated mice as
vehicle controls and two groups of mice treated with two different concentrations of
Tiotropium Bromide.
Figure 2.4 Experimental setup - Memory model of allergic asthma
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Experimental approach for MAM-06.301 treatment in the acute model of
experimental allergic asthma
Mice were sensitized and challenged with low-fat powder milk. They were immunized
by intraperitoneal injection of 10 µg milk in 200 µl 0.9% NaCl, on days 0 and 21.
The mice were exposed to aerosolized milk solution dissolved in 0.9% NaCl, produced
by an ultrasonic nebulizer, following two different protocols. Either twice a day for
one hour with 2% milk solution on two consecutive days (days 28 and 29) or twice
a day for one hour with 2% milk solution on a single day (day 29). The mice were
treated by intraperitoneal injection on 5 consecutive days (days 26 to 30), either with
MAM-06.301 (1 mg/kg once or twice a day dissolved in 0.9% NaCl), with 200 µl
1x PBS (vehicle control group) or with 1 mg/kg dexamethasone (treatment control
group). Mice were lethally anesthetized 24h after the last treatment. There were five
groups of mice per experiment: naive mice as negative controls, PBS-treated mice as
vehicle controls, dexamethasone-treated mice as treatment controls and two groups
of mice treated with MAM-06.301, either once (O.D) or twice (b.i.d) a day.
Figure 2.5 Experimental setup - First experimental approach for acute asthma
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Figure 2.6 Experimental setup - Second experimental approach for acute asthma
Figure 2.7 Experimental setup - Third experimental approach for acute asthma
2.1.3 Setup of experimental allergic asthma, Ba 679 BR
treatment protocol and measurement of AHR in the
BALB/c mouse strain
Mice were sensitized and challenged with ovalbumin. They were immunized by
intraperitoneal injection of 10 µg ovalbumin in 200 µl 1x PBS, on days 0 and
21. The mice were exposed to aerosolized 1% ovalbumin solution dissolved in 1x
PBS, produced by an ultrasonic nebulizer. The mice were administered different
doses of Ba 679 BR (0.00001, 0.0001, 0.001, 0.01, 0.1, 1 and 10 mg/kg) or 1x PBS
intratracheally, once. AHR was measured using a whole body plethysmography at
different timepoints after the treatment day (5h, 24h, 48h, 72h, 96h, 7d, 9d and
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14d). The response of the airways to inhaled methacholine at different concentrations
ranging from 2.5 to 75 mg/ml was recorded. AHR was expressed as enhanced pause
(PenH), a calculated value that correlates with pulmonary resistance.
2.2 Processing of bronchoalveolar fluid, blood and
lung tissue after the assessment
2.2.1 Serum collection
Blood was obtained by heart puncture and clotted at room temperature. After
centrifugation of the clotted blood (15min, 5000 rpm), the sera were separated, kept
in Eppendorf’s tubes and stored at -20◦C until use.
2.2.2 Collection of bronchoalveolar lavage fluid (BALF)
To collect the BALF, the trachea was cannulated using catheter and syringe and the
lungs were lavaged with 2 - 2.5 ml of 1x PBS. The BALF were then centrifuged at
room temperature (10 min, 1500 rpm). Approximately 1.5 ml of supernatant were
gained, transferred into a new Eppendorf tube and kept at -20◦C until use (see 2.5).
The cell pellets were resuspended in 0.5 ml of 1x PBS by vortexing the samples. A
small fraction of the BALF was mixed with trypan blue dye for viable cell counting
on a Neubauer haemocytometer. The other fraction of the BAL fluid was used for
differential cell count.
2.2.3 Preparation of BALF slides by cytospin centrifugation
The fractions of BALF kept for differential cell count were processed centrifuged
again at room temperature (10 min, 1500 rpm), the supernatant thrown away and
the cell pellets resuspended in 1x PBS. The resuspension volume is calculated for
each sample, so that 100 µl of the cell suspension contains 1.105 cells. The slides
were fixed on a metal holder with a plastic funnel, 100 µl of each sample pipetted
into the corresponding funnel and centrifuged using a Cytospin3 (Shandon).
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2.2.4 Analysis of leukocyte subsets by differential cell count of
BALF monolayer after Wright-Giemsa staining
The BALF cytospins were first incubated for 5 min in methanol to fix the tissue,
then in May - Grünwald solution for 15 min. After a washing step in aqua destillata
(aqua dest), the slides were incubated for 20 min in Giemsa solution, washed again
in aqua dest and air dried. The differential cell counts were determined based on
morphological criteria of the different cell types, namely macrophages, eosinophils,
neutrophils and lymphocytes. The counts were performed under light microscope at
100x magnification and a total of 400 cells were counted.
2.2.5 Fixation of the lungs and embedding in paraffin
Lungs with trachea were removed and fixed for at least 4 hours in 4% paraformaldey-
hde. The tissue was dehydrated in an automated process and embedded in paraffin.
2.3 Histopathological staining methods
2.3.1 Deparaffinazation, dehydration and rehydration of the
lung tissue
For all histopathological stainings, 3 to 4 µm-thick lung sections were cut from
paraffin blocks with a microtom and fixed on slides. The deparaffinazation step of
the lung sections consisted in two steps. Firstly, the incubation in xylol, which plays
the role of intermedium, for 20 min, secondly, the incubation at 60-65◦C for 30 min
in an oven. After deparaffinazation, the sections were dehydrated using the following
alternative ascendant ethanol gradient: either 1 min in 100%, 1 min in 96% and 1
min in 80% ethanol or 1 min in 100%, 1 min in 70% and 1 min in 50% ethanol. Both
gradients worked in an equivalent manner. The last step of all stainings was the
rehydration step and consisted in a 5 min incubation of the slides in a descending
ethanol gradient: 50/ 80%, 70/ 96% and 100% ethanol. The slides were then washed
intensively in aqua dest, until the level of water could slide horizontally from the
slides.
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2.3.2 Periodic acid - Schiff staining of lung sections for mucus
producing goblet cells
After deparaffinazation, dehydration and washing of the lung sections, the latter
were incubated for 10 min in 0.5% periodic acid and washed in aqua dest 5 to 6
times. The slides were then incubated in the Schiff’s reagent, which was previously
put in the fridge (4◦C), for 30 min at 60◦C in the oven. Follow then 6 min incubation
in a fresh prepared SO2 water and a step, were the slides were washed for 2-3 min
under luke warm running water. The sections are finally incubated for 19 sec in the
papanicouleous solution and washed directly after this, abundantly under running
luke warm water until the water in the reservoir becomes clear. The lung sections
were rehydrated and incubated for 5 min in n-butylacetate. The slides were then
kept for drying at air temperature for 5 min, mounted with a synthetic resin solution
(Pertex) and covered with appropriate cover slips. The tissues were analyzed at a
20x magnification. To quantify the degree of mucus production, 10 representative
fields of the central airway region of each lung section were chosen and graded from
0 to 5. The grade 0 was given when an airway was completely free from mucus, 5
when all goblet cells of an airway produced mucus massively. If a field contained
more than one airway, the mean of the individual airway grade was calculated. The
grade of mucus production of each mouse lung consisted therefore in the mean of 10
fields in a lung section.
In one experiment histological analyses were quantified differently, detailed informa-
tion are given in 3.3.1.
2.3.3 LUNA staining of lung sections for the presence of
eosinophils in infiltrates
The paraffin lung sections were deparaffinized, dehydrated and washed. These were
then placed for 7.5 min in the working solution. To prepare the working solution,
200 ml of a 1% haematoxylin solution, 8 ml of a 30% ferric chloride solution, 200 ml,
1% acid water and 45 ml of a 1% Biebrich Scarlet solution (Ponceau S) were mixed
together and filtered in a bottle. The next step consisted in dipping 3-4 times the
sections in a 1% acid alcohol solution, followed by an intense washing under running
tap water. The slides were then dipped into a 0.5% lithium carbonate solution until
the colour of the sections changed from pinkish to bluish (3-5 dips) and washed
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abundantly under tap water. The lung sections were rehydrated, dried at RT for 5
min, mounted with Pertex and covered with cover slips. The tissues were analyzed
at 40x magnification. The degree of eosinophil infiltration around airways, blood
vessels and parenchyma was given by the mean eosinophil number of 10 peripheral
foci of a lung section.
In one experiment histological analyses were quantified differently, detailed informa-
tion are given in 3.3.1.
2.3.4 Haematoxylin and eosin staining of lung section for cell
infiltration
The paraffin lung sections were deparaffinized, dehydrated and washed. The slides
were incubated for 5 min in haematoxylin solution, washed by dipping ca. 10 times
in tap water, incubated for 5 sec in 1% acid chloride water and washed again for 5
min under tap water followed by 5 min in aqua dest Place then the slides in 50%
ethanol for 30 sec, in 70% ethanol for 30 sec and in eosin for 30 sec. To remove
the excess of eosin, rinse the slides by dipping in tap water. The lung sections were
rehydrated, dried at RT for 5 min, mounted with Pertex and covered with cover slips.
Pictures showing infiltration of the lung were made at 4x, 20x and 40x magnification.
In one experiment histological analyses were quantified differently, detailed informa-
tion are given in 3.3.1.
2.4 Detection of milk - specific IgG1 in the serum by
ELISA
Each assay was performed on 3 days. Between each step, the wells were washed
by pipetting three times with an ELISA washing buffer containing per liter aqua
dest, 6.06 g Tris and 2 ml Tween20. The sera (first Ab), the second Ab and the
streptavidin-horseradish peroxidase (SA-HRP) were diluted in 0.5% Tween20 solution
in 1x PBS. 96 well plates with flat bottoms were coated with 10 µg/ml milk solution
in 1x PBS overnight at 4◦C. On day 2, unspecific binding sites were blocked by 0.5%
Tween20 for 2h at room temperature followed by the addition of the sera. Each serum
was added in duplicate in the first row of each plate at a starting dilution of 1:100 or
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1:50. A serial dilution of 1:2 was performed. Each plate included a serum-free blank
as negative and a known positive serum for specific IgG1 as a positive control. The
sera were incubated overnight at 4◦C. On day 3, the second Ab (IgG1 biotinylated)
was incubated for 2h at 4◦C at a dilution of 1:5000. Then, the streptavidin-bound
enzyme was added at a dilution of 1:8000 and incubated for 1h at room temperature.
To detect the milk-specific Abs, the substrate was added. TMB was mixed at equal
volumes and incubated for 10 min in the dark. Finally, the plates were analyzed on
an ELISA reader (Spectra Max M5) by the Soft Max Pro 8 software.
2.5 Detection of inflammatory cytokines in BALF
supernatant by ELISA
These ELISA assays were performed by Marinomed. Eotaxin, TNF-α, IL-4, IL-5
and IL-13 concentrations were determined in undiluted BALF supernatants kept
after BALF collection (details see 2.2.2).
2.6 Statistical analysis
Statistical analyses were performed using the GraphPad Prism 5.0 statistical software
for windows (GraphPad Prism, San Diego, CA). Values of absolute cell number and
percentage of BAL cells are expressed as means ± SEM. Score values of histological
gradings are expressed as medians. Data expressed as means ± SEM were evaluated
by two-tailed unpaired T-test and data expressed as medians were analyzed using the
non-parametric Mann-Whitney test. A P value of <0.05 was considered significant.
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3.1 Effect of Tiotropium Bromide on an acute model
of allergic asthma
We used different approaches to test Tiotropium Bromide by varying the aerosol
challenges, the dose and the frequency of administration of the drug.
3.1.1 Effect of Tiotropium Bromide treatment on AHR induced
in an acute model of allergic asthma
AHR to methacholine was assessed by a working group from a laboratory possessing
the adequate apparatus. As the C57BL/6 mouse model of allergic asthma has
attenuated AHR4;56, this parameter was measured on the classical ovalbumin-induced
acute asthma model in BALB/c mice (for details see 2.1.3).
The mice inhaled increasing concentration of methacholine at different timepoints
after instillation of Tiotropium. The control group was administered PBS and
developed strong AHR. Interestingly, Tiotropium seems to have a highly preventive
effect on AHR development in a dose-dependent manner. In the concentration
range from 0.001 to 10 mg/kg but not below, Tiotropium administration protects
mice from developing AHR in response to methacholine. The time period in which
the mice are completely protected from AHR is dose-dependent as well. In fact,
drug concentrations between 0.01 and 10 mg/kg prevented from AHR within 7
days following drug administration, whereas concentrations between 0.001 and 0.01
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mg/kg gave complete protection only up to 72h after Tiotropium treatment. AHR is
re-established 14 days after drug administration in the treated mice, when potential
to develop AHR was already decreased in the positive controls. Tiotropium has an
impressive protective effect on AHR development in the mouse model used, and
exhibits a dose- and time- dependent effect.
3.1.2 First experimental approach of the acute model of
experimental asthma
In the first experimental approach, the mice were given one dose of either 1 or 10
mg/kg Tiotropium Bromide intranasally, one day before the first allergen challenge
and were aerosolized with a 2% milk solution twice a day on two consecutive days.
The mice were sacrificed four days after the treatment day (see Fig.2.1).
Effect of Tiotropium Bromide treatment on inflammatory cells in BALF
The BALF of naive mice is characterized by a high percentage of macrophages
(> 95%) and a low percentage of eosinophils (< 1 %), neutrophils (< 1 %) and
lymphocytes (< 3%) (see Fig.3.1a). Furthermore, naive mice have a highly significant
lower number of total cells in their BALF (< 500,000 cells) compared to the asthmatic
mice (between 2.5 and 3.106 cells, see Fig.3.1b). This disease protocol induced a very
important recruitment of eosinophils into the airways, as they represent 90% of the
cells in the BALF of asthmatic mice. The difference in the cellular BALF constitution
is significant between asthmatic and naive mice for macrophages, neutrophils and
lymphocytes, and highly significant for eosinophils. The treatment administered did
not decrease the percentage of eosinophils in BALF and did not have significant
effects on the total cell number in the BALF or on the number of eosinophils or
lymphocytes. Interestingly, the 1 mg/kg but not the 10 mg/kg treatment had an
effect on the number of neutrophils.
Effect of Tiotropium Bromide treatment on inflammation in lung tissue
Lungs of naive mice are healthy. Severe pulmonary inflammation with eosinophilic
infiltration occurs in the lungs of animals with acute asthma as revealed by histological
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examination. These lungs exhibit very significant goblet cell hyperplasia and mucus
production in the airways compared with naive lungs (see Fig.3.2a and Fig.3.4 A and
B). There is an important cell infiltration forming inflammatory foci around blood
vessels and airways (see Fig.3.6 B). More specifically, we can confirm an infiltration of
mostly eosinophilic nature spreading from the foci into the parenchyma (see Fig.3.2b
and Fig.3.5B). Surprisingly, the treatment did not have beneficial effects on any
aspect of the inflammation as determined by quantitative grading scores (see Fig.3.4
C and D and Fig.3.5 C and D) and qualitative observation of lung infiltration (see
Fig.3.6 C and D).
Effect of Tiotropium Bromide treatment on allergen-specific IgG1
antibodies
In the sera of naive mice, no milk-specific IgG1 antibodies are detected. The IgG1
level in asthmatic mice is low (see Fig.3.3) but confirms the results of previous
experiments performed in our laboratory on the same model. In fact, allergen-specific
IgG1 serum level in asthmatic mice is higher in ovalbumin-sensitized BALB/c mice
than in milk-sensitized C57BL/6 mice. Nevertheless, a significant difference between
the IgG1 level of naive and asthmatic mice is detected at the highest serum dilution
(1:100). However, none of the Tiotropium doses had an effect on the allergen-specific
antibody level. In the 10 mg/kg-treated group more than half of the mice developed
higher antibody levels than the asthmatic mice, but this effect turns out not to be
significant. The groups are heterogeneous concerning their IgG1 production.
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(a) Percentage of individual leukocyte populations in BAL
(b) Total cell counts in BAL
Figure 3.1 Effect of Tiotropium on inflammatory cells in BAL - First experimental
approach for acute asthma. Data are expressed as means ± SEM and represent the
values of two experiments performed under the same conditions. Values from naive mice
represent pooled values of all experiments done with Tiotropium Bromide. Differences
between groups respectively to the cell types were calculated with a two-tailed unpaired
t-test. For total cell number, naive vs vehicle p<0.0001; for macrophage numbers, naive
vs vehicle p=0.0495; for eosinophil numbers, naive vs vehicle p<0.0001; for neutrophil
numbers, naive vs vehicle p=0.0130, vehicle vs Rx 1 mg/kg p=0.0093; for lymphocyte
numbers, naive vs vehicle p=0.0342.
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(a) Mucus production in the airway
(b) Eosinophilic infiltration in the peripheral airways
Figure 3.2 Effect of Tiotropium on mucus production and eosinophil number - First
experimental approach for acute asthma. Data are expressed as medians and represent
the values of two experiments performed under the same conditions. Values from
naive mice represent pooled values of all experiments done with Tiotropium Bromide.
Differences between groups were calculated with a Mann-Whitney test. For PAS, naive
vs vehicle p=0.0039; for LUNA, naive vs vehicle p=0.0003.
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Figure 3.3 Milk-specific IgG1 antibody detection by ELISA - First experimental ap-
proach for acute asthma. Data are expressed as means ± SEM and represent the values
of two experiments performed under the same conditions. Values from naive mice
represent pooled values of all experiments done with Tiotropium Bromide. Differences
between groups were calculated for each serum dilution with a two-tailed unpaired
t-test. At 1:100, naive vs vehicle p=0.0211.
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Figure 3.4 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C and
D) mice. Representative photomicrographs of PAS whole-lung sections for goblet cells
of the airway epithelium - First experimental approach for acute asthma. Objective
lens x200
Figure 3.5 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C and
D) mice. Representative photomicrographs of LUNA whole-lung sections for eosinophil
staining - First experimental approach for acute asthma. Objective lens x600
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Figure 3.6 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C
and D) mice. Representative photomicrographs of H&E whole-lung sections for cell
infiltration - First experimental approach for acute asthma. Objective lens x40, x200
and x400
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3.1.3 Second experimental approach of the acute model of
experimental asthma
In the second set of experiment, the mice were given five doses of either 1 or 0.1
mg/kg Tiotropium Bromide intranasally and were aerosolized with 2% milk solution
twice a day on a single day. Inflammation status was assessed 48h after the last
treatment and the aerosol challenge. After the results of the first set of experiments,
we speculated that an eventual beneficial effect of the drug might not be visible
due to the severity of the disease induced (90% eosinophils in the BALF). We
decided therefore to change the aerosol challenge protocol in order to reach a lower
degree of inflammation and the treatment dose by increasing the frequency of drug
administration. We sacrificed the mice 48h instead of 4 days after the last treatment,
as we supposed that this lapse of time was more adequate to detect the drug effect
(see Fig.2.2).
Effect of Tiotropium Bromide treatment on inflammatory cells in BALF
The effects of the change in the aerosol protocol on the degree of inflammation were
disappointing and below our expectations. Only half of the mice among the asthmatic
group developed sufficient degree of inflammation in the airways as revealed by raw
data on the cellular BALF constitution. Therefore, the asthmatic control group
is characterized by a high heterogeneity between the mice. The responding mice
developed as expected a lower percentage of eosinophils (~40% of BALF cells) than
the mice in the first experimental approach described before (see Fig. 3.1a). In
all groups, the fraction of neutrophils and lymphocytes is low and stays under 2%
(see Fig. 3.7a). Despite the high variability in the asthmatic group, the number of
eosinophils in the BALF differs very significantly from the naive group but does not
exceed 500,000 cells (see Fig. 3.7b). With this disease protocol, no difference in the
total BALF cell number as well as in the number of macrophages, neutrophils and
lymphocytes is observed between the two control groups. A high heterogeneity is
observed in both treated groups as well. Their mean eosinophil percentage varies
around 30% compared to a mean percentage of 20% in the asthmatic group. The
treatments had no effect on any cell type number in the BALF compared to the
asthmatic group.
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Effect of Tiotropium Bromide treatment on inflammation in lung tissue
The histological analysis confirmed the BALF results. The non-responder mice from
the asthmatic group, with almost no eosinophils in their BALF, have a relatively low
pulmonary inflammation and eosinophilic cell infiltration compared to the responding
half of the group. In the treated groups however, no correlation between eosinophil
presence in the BALF and degree of tissue inflammation can be made. In fact, mice
with low mucus production and/or low eosinophilic infiltration are not necessarily the
mice with low eosinophil percentage in their BALF, which is surprising. There is no
significant difference in the degree of mucus production between naive and asthmatic
mice (see Fig.3.8a and Fig.3.10 A and B) indicating that this disease protocol is not
well adapted for this aspect of disease inflammation. The eosinophilic infiltration in
the lung periphery differs very significantly between the control groups (see Fig.3.8b
and Fig. 3.11 A and B) but the treatments had no effect on the eosinophil number
when compared to the asthmatic group (see Fig. 3.11 C and D). The qualitative
analysis of lung infiltration confirms the quantitative results, as administration of
the drug did not seem to have any effect on the grade of cell infiltration in the lung
(see Fig.3.12).
Effect of Tiotropium Bromide treatment on allergen-specific IgG1
antibodies
The general antibody levels are lower than in the first approach, which confirms the
attenuated effect of the modified aerosol challenge. The optical density does not
exceed the value of 1, even for the asthmatic mice (see Fig.3.9). However, at a 1:100
and 1:200 serum dilution, the IgG1 level of asthmatic mice differs significantly from
the level in naive mice. The non-responder animals from the asthmatic group did not
develop specific antibodies like expected. The Tiotropium treatment did not have any
significant influence on the allergen-specific antibody level in the serum of the treated
mice. The treated groups are heterogeneous concerning their antibody response and
in each treated group respectively, one mouse developed higher IgG1 levels than the
asthmatic mice, which is disappointing. Nevertheless, the high variability among the
groups confirms the tendency observed in the histological and cellular analysis of
lungs and airways and could account for a failed detection of treatment effects, if
there exists any.
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(a) Percentage of individual leukocyte populations in BAL
(b) Total cell counts in BAL
Figure 3.7 Effect of Tiotropium on inflammatory cells in BAL - Second experimental
approach for acute asthma. Data are expressed as means ± SEM and represent the
values of two experiments performed under the same conditions. Values from naive mice
represent pooled values of all experiments done with Tiotropium Bromide. Differences
between groups respectively to the cell types were calculated with a two-tailed unpaired
t-test. For eosinophil numbers, naive vs vehicle p=0.0053.
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(a) Mucus production in the airway
(b) Eosinophilic infiltration in the peripheral airways
Figure 3.8 Effect of Tiotropium on mucus production and eosinophil number - Second
experimental approach for acute asthma. Data are expressed as medians and represent
the values of two experiments performed under the same conditions. Values from
naive mice represent pooled values of all experiments done with Tiotropium Bromide.
Differences between groups were calculated with a Mann-Whitney test. For LUNA,
naive vs vehicle p=0.0013.
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Figure 3.9 Milk-specific IgG1 antibody level detected by ELISA - Second experimental
approach for acute asthma. Data are expressed as means ± SEM and represent the
values of two experiments performed under the same conditions. Values from naive mice
represent pooled values of all experiments done with Tiotropium Bromide. Differences
between groups were calculated for each serum dilution with a two-tailed unpaired
t-test. At 1:100, naive vs vehicle p=0.0154; at 1:200, naive vs vehicle p=0.0451.
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Figure 3.10 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C and
D) mice. Representative photomicrographs of PAS whole-lung sections for goblet cells
of the airway epithelium - Second experimental approach for acute asthma. Objective
lens x200
Figure 3.11 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C and
D) mice. Representative photomicrographs of LUNA whole-lung sections for eosinophil
staining - Second experimental approach for acute asthma. Objective lens x400
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Figure 3.12 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C
and D) mice. Representative photomicrographs of H&E whole-lung sections for cell
infiltration - Second experimental approach for acute asthma. Objective lens x40, x200
and x400
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3.1.4 Third experimental approach of the acute model of
experimental asthma
As the protocol of the second experimental approach turned out to be an unadapted
model for our purpose, we modified the aerosol challenge protocol and challenged the
mice with 1% milk solution twice a day on two consecutive days, in order to establish
a more stable disease in the mice. The treatment protocol was kept identical and the
mice were sacrificed 72h after the last challenge and the last treatment respectively
(see Fig.2.3).
Effect of Tiotropium Bromide treatment on inflammatory cells in BALF
The majority of the mice from the asthmatic control group responded to the disease
induction protocol with approximately 70% eosinophils in the BALF. One mouse
distinguishes itself from the other animals of the group with 15% eosinophils in its
BALF and contributes to distort the mean percentage down to 40% (see Fig.3.13a).
In the group treated with 1 mg/kg, one mouse is out of range compared with the
animals of the group and shows a low eosinophil percentage (6%). I hypothesize
this effect to be random, as we know that some mice do not respond to the disease
protocol, more than being a real significant effect of the drug treatment. In the group
treated with 0.1 mg/kg, the drug seems to decrease the percentage of eosinophils in
BALF, from 70% (if we consider only the fraction of the mice in the asthmatic group
which responded) to 40%. Nevertheless, this decrease would have to be confirmed
by further experiments, as a random effect cannot be put by side. In the group
treated with 1 mg/kg, half of the mice have an increased neutrophil percentage (up
to 20%). Beside this, the fraction of neutrophils and lymphocytes is low and stays
under 2%. Although in the percental description of the cell distribution only one
animal has a noticeable low eosinophil ratio, the total cell number exhibits a very
big variation between the mice. The non-responder mouse has the lowest number
of total cells (240,000 cells) but the rest varies between 480,000 and 8.106 cells (see
Fig.3.13b). Nevertheless, the total number of BALF cells, the number of eosinophils
and of lymphocytes of the asthmatic mice differs significantly from the cell number in
the BALF of naive mice. The treatment administered did not influence the cellular
BALF composition of the mice compared to the asthmatic mice. Notice that there
is a high variability among the mice treated with 1 mg/kg.
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Effect of Tiotropium Bromide treatment on inflammation in lung tissue
The mucus production in the lung is very significantly (see Fig.3.14a and Fig.3.16
A and B) and the eosinophilic infiltration significantly different (see Fig.3.14b and
Fig.3.17 A and B) between the two control groups. These parameters were not
attenuated by the treatment, independently of the dose given (Fig.3.16 and Fig.3.17
C and D). Cell infiltration grade assessed by H&E staining confirmed the quantitative
observations (see Fig.3.18).
Effect of Tiotropium Bromide treatment on allergen-specific IgG1
antibodies
Although the intensity of inflammation was expected to increase compared to the
previous setup, the general level of IgG1 is suspiciously very low and the IgG1
level in asthmatic mice does not differ significantly from the level in the naive mice
(see Fig.3.15). Though, in the sera from two of the three responder mice from the
asthmatic group, absolutely no IgG1 is detected.
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(a) Percentage of individual leukocyte populations in BAL
(b) Total cell counts in BAL
Figure 3.13 Effect of Tiotropium on inflammatory cells in BAL - Third experimental
approach for acute asthma. Data are expressed as means ± SEM and represent the
values of two experiments performed under the same conditions. Values from naive mice
represent pooled values of all experiments done with Tiotropium Bromide. Differences
between groups respectively to the cell types were calculated with a two-tailed unpaired
t-test. For total cell number, naive vs vehicle p=0.0245; for eosinophil numbers, naive
vs vehicle p=0.0172; for lymphocytes, naive vs vehicle p=0.0456.
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(a) Mucus production in the airway
(b) Eosinophilic infiltration in the peripheral airways
Figure 3.14 Effect of Tiotropium on mucus production and eosinophil number - Third
experimental approach for acute asthma. Data are expressed as medians and represent
the values of two experiments performed under the same conditions. Values from
naive mice represent pooled values of all experiments done with Tiotropium Bromide.
Differences between groups were calculated with a Mann-Whitney test. For PAS, naive
vs vehicle p=0.0032; for LUNA, naive vs vehicle p=0.0131.
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Figure 3.15 Milk-specific IgG1 antibody detection by ELISA - Third experimental
approach for acute asthma. Data are expressed as means ± SEM and represent the
values of two experiments performed under the same conditions. Values from naive mice
represent pooled values of all experiments done with Tiotropium Bromide. Differences
between groups were calculated for each serum dilution with a two-tailed unpaired
t-test.
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Figure 3.16 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C and
D) mice. Representative photomicrographs of PAS whole-lung sections for goblet cells
of the airway epithelium - Third experimental approach for acute asthma. Objective
lens x200
Figure 3.17 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C and
D) mice. Representative photomicrographs of LUNA whole-lung sections for eosinophil
staining - Third experimental approach for acute asthma. Objective lens x400
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Figure 3.18 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C
and D) mice. Representative photomicrographs of H&E whole-lung sections for cell
infiltration - Third experimental approach for acute asthma. Objective lens x40, x200
and x400
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3.2 Effect of Tiotropium Bromide on a memory
model of allergic asthma
We investigated the effect of the drug administration during another phase of disease
simulation. In this memory model, an acute asthma phase was induced like described
before. For acute disease, the mice were aerosolized with a 2% milk solution twice
a day on a single day. After a rest of approximately 110 days (~3.5 months) that
simulates disease remission, the mice were rechallenged with 1% milk solution twice
a day on two consecutive days for disease exacerbation. We treated the mice intrana-
sally with 1 mg/kg or 0.1 mg/kg of the drug on five consecutive days, before disease
relapse. The mice were sacrificed 72h after the last challenge and the last treatment
respectively (see Fig.2.4).
3.2.1 Effect of Tiotropium Bromide treatment on inflammatory
cells in BALF
All the so-called “memory mice”, meaning the mice with a relapsing disease, present
around 75% eosinophils in their BALF (see Fig.3.19a). In each of both treated groups,
the percentage of eosinophils is constant, the groups are homogeneous respectively.
The mean percentage of eosinophils of the animals treated with 1 mg/kg slightly
decreases to 60%. No effect on the eosinophil fraction is detected in the group
receiving 0.1 mg/kg, compared to the asthmatic group. Neutrophils and lymphocytes
do not exceed 3% of the total cells. The total cell number in the BALF of naive mice
(around 500,000 cells) differs highly significantly from the extremely high number
of cells counted in the BALF of asthmatic mice, which varies between 5 and 10.106
(see Fig.3.19b). The number of neutrophils, macrophages, and eosinophils, but
not lymphocytes, differs significantly to highly significantly respectively between
asthmatic and naive mice. Interestingly, the 1 mg/kg treatment have a significant
effect on the total BALF cell number and on the number of eosinophils compared to
the positive control group.
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3.2.2 Effect of Tiotropium Bromide treatment on inflammation
in lung tissue
The mucus production in the lung differs very significantly between the two control
groups (see Fig.3.20a and Fig.3.22 A and B) as well as the eosinophilic infiltration
(see Fig.3.20b and Fig.3.23 A and B). These parameters were not attenuated by the
treatment, independently of the dose given (Fig.3.22 and Fig.3.23 C and D). An
effect of the 1 mg/kg treatment on the eosinophil number in the lung periphery is not
big enough to be significantly different from the number in the lungs of asthmatic
mice, which is confirmed by the qualitative observations of the H&E staining (see
Fig.3.24).
3.2.3 Effect of Tiotropium Bromide treatment on
allergen-specific IgG1 antibodies
The analysis of the asthmatic mice sera indicate, as in my previous experiments, a
very low level of IgG1. Except for one mouse of the group treated with 1 mg/kg of
the compound, the IgG1 level in the sera of the treated animals is elevated compared
to the IgG1 level in the sera of asthmatic mice (see Fig.3.21). There is a significant
difference in the IgG1 levels between asthmatic and naive mice at a 1:100 dilution
but not at 1:50, probably because of the high variability among the group at a 1:50
dilution. At 1:50 and 1:100, the IgG1 levels of the 0.1 mg/kg treated mice differ
significantly from the levels in the asthmatic group.
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(a) Percentage of individual leukocyte populations in BAL
(b) Total cell counts in BAL
Figure 3.19 Effect of Tiotropium on inflammatory cells in BAL - Memory model of
experimental asthma. Data are expressed as means ± SEM and represent the values of
two experiments performed under the same conditions. Values from naive mice represent
pooled values of all experiments done with Tiotropium Bromide. Differences between
groups respectively to the cell types were calculated with a two-tailed unpaired t-test.
For total cell number, naive vs vehicle p<0.0001, vehicle vs Rx 1 mg/kg p=0.0175;
for macrophage numbers naive vs vehicle p=0.0021, for eosinophil numbers, naive vs
vehicle p<0.0001, vehicle vs Rx 1 mg/kg p=0.0033; for neutrophils, naive vs vehicle
p=0.0119.
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(a) Mucus production in the airway
(b) Eosinophilic infiltration in the peripheral airways
Figure 3.20 Effect of Tiotropium on mucus production and eosinophil number - Memory
model of experimental asthma. Data are expressed as medians and represent the values
of two experiments performed under the same conditions. Values from naive mice
represent pooled values of all experiments done with Tiotropium Bromide. Differences
between groups were calculated with a Mann-Whitney test. For PAS, naive vs vehicle
p=0.0032; for LUNA, naive vs vehicle p=0.0013.
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Figure 3.21 Milk-specific IgG1 antibody detection by ELISA - Memory model of
allergic asthma. Data are expressed as means ± SEM and represent the values of two
experiments performed under the same conditions. Values from naive mice represent
pooled values of all experiments done with Tiotropium Bromide. Differences between
groups were calculated for each serum dilution with a two-tailed unpaired t-test. At
1:50, vehicle vs Rx 0.1 mg/kg p=0.0356; at 1:100, naive vs vehicle p=0.0484, vehicle vs
Rx 0.1 mg/kg p=0.0398.
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Figure 3.22 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C and
D) mice. Representative photomicrographs of PAS whole-lung sections for goblet cells
of the airway epithelium - Memory model of allergic asthma. Objective lens x200
Figure 3.23 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C and
D) mice. Representative photomicrographs of LUNA whole-lung sections for eosinophil
staining - Memory model of allergic asthma. Objective lens x400
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Figure 3.24 Lung histology in naive (A), asthmatic (B) and Tiotropium-treated (C
and D) mice. Representative photomicrographs of H&E whole-lung sections for cell
infiltration - Memory model of allergic asthma. Objective lens x40, x200 and x400
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3.3 Effect of MAM-06.301 on an acute model of
allergic asthma
Three experimental approaches were used to test this compound. The protocols
differ in the aerosol challenges and in the frequency of the treatments but neither in
the dose of MAM-06.301 nor in the dose of dexamethasone administered. Both were
always used at a concentration of 1 mg/kg.
3.3.1 First experimental approach of the acute model of
experimental asthma
In the first set of experiment the mice were given MAM-06.301 intraperitoneally
on five consecutive days and aerosolized with 2% milk solution twice a day on two
consecutive days. The mice were assessed 72h after the last challenge and 24h after
the last treatment (see Fig.2.5). Like mentioned in 2.3, this experiment was carried
out by my colleague Lamia El-Housseiny, whose quantitative histological analysis
criteria’s are different than mine. Detailed information is given below.
Effect of MAM-06.301 treatment on inflammatory cells in BALF
In this experiment, the control groups differ significantly from each other concerning
the eosinophil number in the BALF (see Fig.3.25b). Whereas these cells are almost
absent in naive mice, asthmatic mice have over 2.106 eosinophils in their BALF.
Compared to the vehicle group, dexamethasone treatment reduced very significantly
the number of eosinophils down to 100,000. The trend between control groups is
reflected also in terms of percentage. In fact, asthmatic mice have around 70% and
dexamethasone-treated mice around 20% eosinophils in their BALF (see Fig.3.25a).
In none of the groups, neutrophils are present and lymphocyte number does not
differ between naive, vehicle and dexamethasone-treated groups. However, although
MAM-06.301 treatment affected neither the eosinophil number nor its percentage in
BALF, the number of lymphocytes differs significantly from the BALF of asthmatic
mice in the MAM-06.301-treated group.
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Effect of MAM-06.301 treatment on inflammation in lung tissue
For quantification of eosinophilic infiltration based on LUNA staining, the cells were
counted in the parenchyma by distinguishing between central (large airways) and
peripheral (small airways) lung first. Further analysis discerned between eosinophils
localized around the airway (peribronchial) or around the blood vessel (perivascular).
Concerning the eosinophil number, very significant differences between asthmatic and
naive mice, and significant differences between asthmatic and dexamethasone-treated
mice are observed in both central and peripheral sections of the parenchyma (see
Fig.3.26b). Furthermore, these differences are also displayed in areas around airways
in blood vessels. Interestingly, MAM-06.301 affects significantly the number of
eosinophils in central and peripheral lung, as well as around the airways. However,
it has no effect on eosinophils around the blood vessels.
The intensity of mucus production in the airways was quantified by determining
the amount of positive stained goblet cells (which are the cells producing mucus) in
the totality of the lung section and furthermore by differentiating between mucus
production in central and peripheral airways. With this disease model, the mucus
production differs very significantly between asthmatic and naive mice from the cen-
tral to the peripheral located airways (see Fig.3.26a). MAM-06.301 has a significant
effect only on the mucus production of small airways situated in the lung periphery.
Using the same criteria for discernment of lung areas, cell infiltration reflected by
H&E staining was quantified using the grading method described before105.
Cell infiltration is very significantly different between asthmatic and naive mice as
well as between asthmatic and dexamethasone-treated mice in lung parenchyma (see
Fig.3.26c). MAM-06.301 had a very significant effect on the peribronchial infiltration
compared to the peribronchial infiltration in the lungs of asthmatic mice.
Effect of MAM-06.301 treatment on inflammatory cytokines in the BALF
supernatant
The variability among each group is high concerning all cytokines of interest, namely
eotaxin, TNF-α, IL-4, IL-5 and IL-13 (see Fig.3.27). The asthmatic mice seem
to have elevated IL-4, IL-5 and IL-13 levels in their BALF supernatant compared
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to naive mice. Surprisingly dexamethasone does not seem to reduce any of these
inflammatory mediators. Nevertheless, these analyses indicate an eventual effect of
MAM-06.301 on IL-5, which plays a critical role in differentiation of eosinophils and
in the sustainability of eosinophilic inflammation.
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(a) Percentage of individual leukocyte populations in BAL
(b) Total cell counts in BAL
Figure 3.25 Effect of MAM-06.301 on inflammatory cells in BAL - First experimental
approach for acute asthma. Data are expressed as means ± SEM. Differences between
groups respectively to the cell types were calculated with a two-tailed unpaired t-test.
For eosinophil numbers, naive vs vehicle p=0.0008, vehicle vs dex. p=0.0010; for
lymphocytes, vehicle vs Rx O.D p=0.0410.
65
Chapter 3 Results
(a) Mucus production in the airway
(b) Eosinophilic infiltration in the peripheral airways
(c) Cell infiltration in the airways
Figure 3.26 Effect of MAM-06.301 on mucus production and cell infiltration - First
experimental approach for acute asthma. Data are expressed as medians. Differences
between groups were calculated with a Mann-Whitney test. For PAS, LUNA and H&E
in all areas of the lung, naive vs vehicle p=0.0097. For PAS goblet, vehicle vs dex.
p=0.0117; for PAS peripheral AW, vehicle vs Rx O.D p=0.0236. For LUNA central
lung, lung vehicle vs dex. and vehicle vs Rx O.D p=0.0117; for LUNA peripheral lung,
vehicle vs dex. p=0.0119, vehicle vs Rx O.D p=0.0273; for LUNA peribronchial, vehicle
vs dex. p=0.0079, vehicle vs Rx O.D p=0.0317; for LUNA perivascular, vehicle vs dex.
p=0.0212. For H&E lung and peribronchial, vehicle vs dex. and vehicle vs Rx O.D
p=0.0097; for H&E perivascular, vehicle vs dex. p=0.0129.
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Figure 3.27 Cytokines in BAL supernatant - First experimental approach for acute
asthma
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3.3.2 Second experimental approach of the acute model of
experimental asthma
In the second set of experiment the mice were administered MAM-06.301 intraperi-
toneally on seven consecutive days, either once (Rx O.D) or twice daily (Rx b.i.d),
and aerosolized with 2% milk solution twice a day on two consecutive days. The
mice were sacrificed 72h after the last challenge and 24h after the last treatment (see
Fig.2.6).
Effect of MAM-06.301 treatment on inflammatory cells in BALF
In the BALF of the asthmatic mice, approximately 65% of the cells are eosinophils.
Two mice from the asthmatic group developed a much lower percentage of eosinophils
(40% and 20%) than the others and influence the variability among the group (see
Fig.3.28a). In the treatment control group, all mice should have decreased eosinophils
in their BALF, as the beneficial effect of dexamethasone is known. The percentage
of lymphocytes and neutrophils stays under the 6% barrier. Like expected, the
total number of BALF cells differs very significantly between the asthmatic mice
(3.106 cells) and the naive mice (< 500,000 cells) as well as significantly between
the asthmatic and the dexamethasone-treated mice (<1.106 cells, see Fig.3.28b).
Interestingly, the number of eosinophils and neutrophils differ significantly and very
significantly between the three control groups. Dexamethasone had a significant
effect on the number of macrophages but not on the number of lymphocytes in the
BALF compared to asthmatic mice. Unfortunately, the treatment with MAM-06.301
had no effect on the total BALF cell number or on the cellular BALF composition.
Effect of MAM.06.301 treatment on inflammation in lung tissue
The histological quantitative analysis of the mucus production in the airways con-
firmed the difference expected in the control groups. Asthmatic mice have a degree
of mucus produced that differs highly significantly from the production in the naive
and significantly from the mucus production in the dexamethasone-treated groups
(see Fig.3.29a and Fig.3.31 A, B and C). Surprisingly, the twice a day treatment
showed a significant effect on the mucus production compared to the asthmatic
mice. Almost half of the mice in the once a day treatment group did not seem to
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respond to the treatment. Even if the extent of the eosinophilic infiltration in the
asthmatic group differs very significantly from the naive group (see Fig.3.29b and
Fig.3.32 A and B), half of the mice have a clearly higher degree of infiltration than
the others. This might be the reason why the control treatment as well as both
MAM.06.301 treatments have no significant effect on the peripheral eosinophilic
infiltration, compared to the asthmatic mice (see Fig.3.32 C, D and E). Interestingly,
the qualitative analysis based on the H&E staining testifies the decreased infiltration
in the control-treated as well as in the MAM.06.301-treated groups (see Fig.3.33).
Effect of MAM-06.301 treatment on allergen-specific IgG1 antibodies
The naive mice have no IgG1 antibodies in their sera, but the control groups (asth-
matic and dexamethasone-treated) do not differ significantly from it (see Fig.3.30).
In this case, no statement is possible concerning the effect of the substance, as the
control groups are not reliable.
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(a) Percentage of individual leukocyte populations in BAL
(b) Total cell counts in BAL
Figure 3.28 Effect of MAM-06.301 on inflammatory cells in BAL - Second experimental
approach for acute asthma. Data are expressed as means ± SEM and represent the
values of two experiments performed under the same conditions. Differences between
groups respectively to the cell types were calculated with a two-tailed unpaired t-
test. For total cell number, naive vs vehicle p=0.0066, vehicle vs dex. p=0.0173; for
macrophage numbers, naive vs vehicle p=0.0250; for eosinophil numbers, naive vs
vehicle p=0.0059, vehicle vs dex. p=0.0201; for neutrophils, naive vs vehicle p=0.0092,
vehicle vs dex. p=0,0118; for lymphocytes, naive vs vehicle p=0,0247.
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(a) Mucus production in the airway
(b) Eosinophilic infiltration in the peripheral airways
Figure 3.29 Effect of MAM-06.301 on mucus production and eosinophil number - Second
experimental approach for acute asthma. Data are expressed as medians and represent
the values of two experiments performed under the same conditions. Differences between
groups were calculated with a Mann-Whitney test. For PAS, naive vs vehicle p=0.0006,
vehicle vs dex. p=0.0115, vehicle vs Rx b.i.d p=0.0271; for LUNA, naive vs vehicle
p=0.0025
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Figure 3.30 Milk-specific IgG1 antibody level detected by ELISA - Second experimental
approach for acute asthma. Data are expressed as means ± SEM and represent the
values of two experiments performed under the same conditions.
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Figure 3.31 Lung histology in naive (A), asthmatic (B), dexamethasone-treated (C)
and MAM-06.301-treated (D and E) mice. Representative photomicrographs of PAS
whole-lung sections for goblet cells of the airway epithelium - Second experimental
approach for acute asthma. Objective lens x200
Figure 3.32 Lung histology in naive (A), asthmatic (B), dexamethasone-treated (C)
and MAM-06.301-treated (D and E) mice. Representative photomicrographs of LUNA
whole-lung sections for eosinophil staining - Second experimental approach for acute
asthma. Objective lens x400
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Figure 3.33 Lung histology in naive (A), asthmatic (B), dexamethasone-treated (C)
and MAM-06.301-treated (D and E) mice. Representative photomicrographs of H&E
whole-lung sections for cell infiltration - Second experimental approach for acute asthma.
Objective lens x40, x200 and x400
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3.3.3 Third experimental approach
In the third set of experiment the mice were administered MAM-06.301 intraperi-
toneally on five consecutive days, either once (Rx O.D) or twice daily (Rx b.i.d) but
aerosolized with 2% milk solution twice a day on one single day for the same reasons
than described in 3.1.3. The mice were assessed 72h after the last challenge and 24h
after the last treatment (see Fig.2.7).
Effect of MAM-06.301 treatment on inflammatory cells in BALF
The percentage of eosinophils decreased to approximately 30% after the modifi-
cations brought to the disease induction protocol (see Fig.3.34a). Lymphocytes
and neutrophils do not exceed 1%. Taken together these changes did not give the
expected results that turned out to be rather disappointing. In fact, none of the
groups, including the control groups, differ from each other concerning both their
total BALF cell number and their BALF cell composition (see Fig.3.34b). A reason
for this could be the very high variability among the groups, which would indicate
that this disease setup is unreliable.
Effect of MAM.06.301 treatment on inflammation in lung tissue
The problem encountered in disease induction is reflected in the histological lung
analysis. Even if the asthmatic group still differs very significantly from the naive mice
in terms of mucus production (see Fig.3.35a and Fig.3.37 A and B) and eosinophilic
infiltration (see Fig.3.35b Fig.3.38 A and B), dexamethasone and both MAM.06.301
treatments had no effect on these parameters (see Fig.3.37 and 3.38 C, D and E).
As the necessary difference between positive and treatment control group does not
appear, no conclusions can be drawn concerning an effect of the drug. In the H&E
staining though, dexamethasone and to a lesser extent MAM.06-301 seem to decrease
cell infiltration (see Fig.3.39).
Effect of MAM-06.301 treatment on allergen-specific IgG1 antibodies
Like expected, the IgG1 levels in the sera of all mice are lower than in the first setup.
Naive mice have no IgG1, but similarly to the previous experiment, the antibody
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levels in the mice of the control groups do not differ significantly from the naive
mice (see Fig.3.36). The results are unsatisfying and due to problems to induce IgG1
in asthmatic mice with this model, we cannot speculate on an eventual effect of
MAM-06-301 on the allergen-specific IgG1 production.
(a) Percentage of individual leukocyte populations in BAL
(b) Total cell counts in BAL
Figure 3.34 Effect of MAM-06-301 on inflammatory cells in BAL - Third experimental
approach for acute asthma. Data are expressed as means ± SEM. Differences between
groups respectively to the cell types were calculated with a two-tailed unpaired t-test.
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(a) Mucus production in the airway
(b) Eosinophilic infiltration in the peripheral airways
Figure 3.35 Effect of MAM-06-301 on mucus production and eosinophil number - Third
experimental approach for acute asthma. Data are expressed as medians and represent
the values of two experiments performed under the same conditions. Differences between
groups were calculated with a Mann-Whitney test. For PAS, naive vs vehicle p=0.0092;
for LUNA, naive vs vehicle p=0.0025
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Figure 3.36 Milk-specific IgG1 antibody detection by ELISA - Third experimental
approach for acute asthma
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Figure 3.37 Lung histology in naive (A), asthmatic (B), dexamethasone-treated (C)
and MAM-06.301-treated (D and E) mice. Representative photomicrographs of PAS
whole-lung sections for goblet cells of the airway epithelium - Third experimental
approach for acute asthma. Objective lens x200
Figure 3.38 Lung histology in naive (A), asthmatic (B), dexamethasone-treated (C)
and MAM-06.301-treated (D and E) mice. Representative photomicrographs of LUNA
whole-lung sections for eosinophil staining - Third experimental approach for acute
asthma. Objective lens x400
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Figure 3.39 Lung histology in naive (A), asthmatic (B), dexamethasone-treated (C)
and MAM-06.301-treated (D and E) mice. Representative photomicrographs of H&E
whole-lung sections for cell infiltration - Third experimental approach for acute asthma.
Objective lens x40, x200 and x400
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Discussion
Asthma is a major health problem as demonstrated by its global increase in prevalence
and incidence. Patients suffering from allergic asthma have recurrent episodes of
coughing, wheezing, breathlessness and chest tightness. These symptoms are the
consequence of chronic airways inflammation and airway hyperresponsiveness to
allergens, leading to mucus hypersecretion and reversible airway obstruction. No
cure exists for asthma. Currently, the most effective anti-asthmatic treatments
available aim to relieve bronchoconstriction and control airway inflammation with a
combination of glucocorticoids and beta-adrenoceptor agonists. However, there is a
subpopulation of patients who are resistant to therapy. This project was focused on
finding novel therapeutics for the treatment of allergic asthma.
4.1 Experimental mouse model of milk-induced
allergic asthma
4.1.1 Usefulness of our mouse model
To test novel therapeutics, we used a model of allergic asthma developed in the
laboratory using the allergen, milk. Milk is a useful antigen/allergen because it is a
naturally occurring allergen, which generates an allergic response to a combination
of proteins, mimicking allergic asthma in patients and it is much less expensive than
purified proteins like ovalbumin. When sensitized and aerosol-challenged with milk,
mice develop key features of allergic disease, including allergic lung inflammation,
airway hypersecretion of mucus and production of antigen-specific IgE. Interestingly,
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C57BL/6 (B6) mice respond more severely to milk, compared to the more "allergic"
type BALB/c mouse strain. Thus, we adopted B6 mice to study the effects of two
compounds with different mechanisms to inhibit allergic asthma. We measured
airway and parenchymal inflammation, allergen-specific IgG1 antibodies in the serum
and hypersecretion of mucus in lungs. We tested the compounds during the onset of
allergic disease and then sought to determine whether the compounds could prevent
an allergen-induced exacerbation50;87. Tiotropium Bromide was tested on the acute
and exacerbation asthma models and MAM-06.301 was tested during acute disease
onset.
4.1.2 Effect on allergic airway inflammation
Mice were sensitized by 2 i.p injections of a solution of low-fat milk powder dissolved
in PBS for primary allergen priming followed by respiratory tract allergen exposure
with a nebulized milk solution. Mice were first challenged with four 2% milk solution
aerosolizations but our results revealed that the extent of disease was too severe and
thus, difficult to detect a treatment effect. Indeed, we observed a 75% infiltration of
eosinophils and a similar level of parenchymal inflammation upon in situ histological
analysis. This led us to modify the protocol to generate more moderate disease severity.
We tested three different protocols (four 1% vs two 2% solution aerosolizations vs a
single i.n instillation) and compared disease outcome (data not shown). Based on a
moderate degree of inflammation, we adopted a “two-2%-solution” protocol. Our
results confirmed the influence of changing the dose and frequency of aerosolizations
on the extent of disease illustrated as an overall decrease of inflammation. While
this protocol was promising, there was an unexpected increase in mouse-to-mouse
variation that precluded its use. Using another protocol with “four-1%-solution”, we
observed less variation and proceeded with the compound investigation. To study the
effect of the compound on the prevention of disease exacerbation, we used recovered
mice (in remission) and induced a disease relapse with four 1% milk challenges.
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4.2 New insights on the effect of the novel
compounds on inflammation processes
4.2.1 Investigations on a new indication for Tiotropium
Bromide
Asthma was induced in mice by i.p injections of 10 mcg milk in 200 mcl 1x PBS
on days 0 and 21, to prime an allergic immune response against milk. One week
later, we aerosolized mice with either a 2 or 1 % milk solution. To test Tiotropium,
we used intranasal instillation because our past experience, and that of others, has
shown that it is as effective as intratracheal instillation. Intranasal instillation
also has another advantage, which is that it is a minimally invasive method that
is performed on conscious mice. Importantly, we used local administration of
Tiotropium, as it is already available for inhalation therapy for other indications.
Thus, Tiotropium was instilled directly to the site of inflammation in the lungs. To
ensure consistent and accurate dosing, we administered the drug in a small volume
of 50 mcl 1xPBS47. The technique is simpler than inhalation exposure used in
some studies21, where meticulous calibration and high amount of drug represent
considerable limits47. Tiotropium is a muscarinic receptor antagonist, which we
predicted would predominantly reduce AHR and mucus hypersecretion. An important
property of Tiotropium is its kinetic selectivity for M1 and M3-receptors over M2-
receptors6;43;69. In fact, M1-receptors facilitate cholinergic neurotransmission and
therefore enhance cholinergic bronchoconstriction, whereas M3-receptors on airway
smooth muscle cells and glands mediate bronchoconstriction and mucus secretion.
M2-receptors at cholinergic nerve endings inhibit the release of ACh and therefore
act as feedback inhibitory receptors (autoreceptors)6. Taken together, Tiotropium’s
long-acting targeted blockade of ACh release, suggest a beneficial effect on AHR and
mucus production in asthma.
Effect of Tiotropium Bromide on AHR and mucus production We found that
Tiotropium was highly effective in the prevention of AHR in acute asthma, as
expected because ACh-mediates bronchoconstriction6. Tiotropium also inhibits
airway M3-receptor-mediated mucus production, which is the reason we expected an
effect on mucus hypersecretion. Surprisingly, mucus production remained unaffected
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in our experiments. In contrast, there are studies in animal models showing that
Tiotropium reduces allergen-induced mucus gland hypertrophy21 and airway smooth
muscle remodeling59. Inhaled anticholinergic agents are used for the treatment of
chronic lung diseases in humans122. Although it is not clear why mucus production
was unaffected by Tiotropium. One possibility is that the complete dose did not reach
the inflamed areas in the lungs and that perhaps nebulization would have been more
effective because the particle size is smaller (3nm) and the drug would reach the more
distant segments of the lungs. Another possibility is based on studies addressing
the effect and mechanisms of action of Tiotropium that were either done in vitro
on guinea pig trachea and human bronchi or in vivo on lung membranes of guinea
pigs, dogs and humans6. These other animals may respond differently than mice. A
third possibility involves recent studies illustrating that there are differences in the
neuronal nicotinic ACh receptor between mouse strains57;124. In our studies, AHR
experiments with Tiotropium were done with BALB/c mice because B6 mice do not
develop AHR. It is possible that B6 mice are resistant to the M3-receptor blocking
effect of Tiotropium and thus, we did not observe effects on mucus production.
Future experiments using OVA, as an allergen in BALB/c mice will be done to
further characterize the effect of Tiotropium on mucus production.
Effect of Tiotropium Bromide on lung inflammation Interestingly, 1 mg/kg of
Tiotropium had a significant effect on airway inflammation during disease exacer-
bation. The overall severity and eosinophilia were reduced upon treatment. We
expected that the drug would reduce inflammation during acute disease onset, but it
was only able to reduce inflammation during exacerbation. These results support our
previous results indicating that corticosteroids are able to inhibit chronic ongoing
allergic asthma compared to acute disease88. These results confirm that it is easier
to treat ongoing or chronic allergic asthma than it is to prevent acute onset disease.
Tiotropium is indicated for the treatment of COPD but not for asthma. There are
interesting similarities between COPD and severe asthma, which has an inflamma-
tion pattern that differs from the mild to moderate asthma13;127. A few common
properties of both chronic lung diseases include increased numbers of neutrophils in
the sputum, increased amount of CXCL8 and TNF, oxidative stress, low sensitivity
to glucocorticoids, acute exacerbations and activation of NFκB7;26;49;80;83. These
similarities have spurned the development of new therapeutic approaches44;95. Our
results support the idea that Tiotropium may be better at treating inflammation
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in severe asthma, which is more similar to COPD. Tiotropium may have additional
features that make it promising for the treatment for allergic asthma. Muscarinic
receptor signaling appears to play a role in the pathophysiology of asthma and
COPD60. There is some suggestion that Tiotropium could inhibit airway remodeling
and diminished lung function, in addition to its role as a bronchodilator44. In a
study in a chronic guinea pig model of asthma, Tiotropium was as effective as the
steroid budenoside, in inhibiting airway remodeling21. Recently, Tiotropium has
been found to be effective for severe asthma with a non-eosinophilic phenotype86 in
humans, which may explain the lack of effect on eosinophilic inflammation in the
airways and lung tissue observed in our experiments. Previous studies have reported
a relationship between airway remodeling and asthma severity76 and according to
others, airway remodeling would explain the lack of response to therapy in some
patients. By taking into account the important role of ACh in airway remodeling
and the strong association between airway remodeling and severe asthma, it is
conceivable that Tiotropium would stand the test in a chronic asthma model in
future experiments. Tiotropium may be more potent when used in combination
with anti-inflammatory agents. One study has shown that the anticholinergic drug
glycopyrrolate acts synergistically with the PDE4 inhibitor rolipram and budesonide
in inhibiting inflammatory mediators115. In another study, the beta-adrenoceptor
agonist carmoterol had an additive effect when combined with Tiotropium125.
4.2.2 The natural component MAM-06.301 for a new
application
We tested the effect of MAM-06.301, on acute onset allergic asthma using intraperi-
toneal injections because this route of administration had already been successfully
used in other experiments. The mice were treated with 1 mg/kg of the drug, either
once (O.D.) or twice a day (b.i.d). Control groups were treated with the same
dose of the corticosteroid, dexamethasone, which is the best known treatment for
allergic asthma in patients and in mouse models. Asthma is characterized by the
expression of multiple genes for inflammatory proteins regulated by transcription
factors. Several transcription factors are involved in asthmatic inflammation and
lead to coordinate expression of multiple inflammatory mediators. Recent findings
indicate that MAM-06.301 might inhibit NFκB108, which has been associated with
recruitment of eosinophils by eotaxin and activation of macrophages and epithelial
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cells through iNOS (inducible form of nitric oxide synthase)8;70;121. MAM-06.301 may
be therefore useful in the treatment of asthma associated with oxidative stress. MAM-
06.301 had not yet been tested in allergic asthma, however, we hypothesized that it
may attenuate disease via its anti-edematous and anti-inflammatory properties. Ad-
ditionally, MAM-06.301 had been shown previously to exhibit anti-allergic properties
in other disease models (personal communication, Dr. E. Prieschl-Grassauer).
Effect of MAM-06.301 on mucus production and lung inflammation Our re-
sults show an effect of MAM-06.301 on mucus secretion in peripheral airways and
on inflammation. We detected decreased mucus secretion and inflammatory cell
infiltration after administering both 7 and 10 doses. In contrast, 7 days of once a day
treatment reduced eosinophilic infiltration whereas, 10 doses delivered in 5 days did
not. An explanation could be that the drug acts better when given during a longer
period of time. An explanation could be that the drug acts better when given during
a longer period of time. Taken together, MAM-06.301 is able to decrease overall
inflammation more rapidly, than the number of eosinophils, which may indicate a
time-dependent effect of the drug on eosinophils. Moreover, the effect of MAM-06.301
may be even more relevant in a model, where acute inflammation is dampened and
resembles more the degree of inflammation seen in humans (see 4.1.2). Nevertheless,
our results give promising perspective for the therapeutic use of MAM-06.301 on
mucus hypersecretion and inflammation in allergic asthma.
Effect of MAM-06.301 on airway inflammation MAM-06.301 exhibits anti-
inflammatory properties in different disease models23;52;53;104;120. Surprisingly, MAM-
06.301 treatment did not modulate airway inflammation. It is not clear why this
anti-inflammatory drug was ineffective in the airways. However, there are several
possible explanations. One possibility is that the systemic route of administration
was ineffective because it did not reach high enough concentrations in the lungs.
Because it is possible to deliver drugs locally in allergic asthma, the future plan in
the lab is to attempt to use MAM-06.301 intranasally. A second explanation for
the lack of response may be because the dose was insufficient. In this case, it is
important to increase the dosing, by increasing either the dose or the frequency of
administration.
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Effect of MAM-06.301 in allergic asthma MAM-06.301 has other important
effects that may be useful for the treatment of allergic asthma. It has been shown to
regulate the cell cycle growth of colon cancer cells by inducing p21 (waf1/cip1)117.
MAM-06.301 may act on lung epithelial cells and airway remodeling, which would
potentially make it an interesting drug for chronic allergic asthma where airway
remodeling causes lung damage. This effect of, MAM-06.301 may make it an ideal
drug for its influence on hyaluronidase activity, which interferes with proteoglycan
metabolism by bronchial fibroblasts that may contribute to AHR in asthma147.
This is supported by a study illustrating that hyaluronic acid plays a role in the
development of fibrotic changes in the lung of rats65. It would, therefore, be intriguing
to investigate whether the anti-hyaluronidase activity of MAM-06.30152 can improve
subepithelial fibrosis implicated in asthma1. MAM-06.301 also has anti-edema
properties, which would be an additional useful adjuvant effect of the drug for
allergic asthma123.
4.3 Summary
New insights and promising perspectives have been gained on the role of Tiotropium
Bromide and MAM-06.301 in an experimental mouse model of allergic asthma. We
used a milk-induced B6 mouse model of allergic asthma for evaluation of mucus
production, lung inflammation and serum immunoglobulin. An ovalbumin-induced
BALB/c mouse model of allergic asthma was used to evaluate methacholine-induced
AHR after Tiotropium treatment. Our results indicate that Tiotropium Bromide
efficiently prevents AHR development for up to 7 days, in a dose-dependent manner,
inhibited lung inflammation during disease exacerbation but did not modulate mucus
hypersecretion. Tiotropium Bromide is in clinical use for COPD and may be useful for
allergic asthma. However, more experiments need to be done. Our investigations with
MAM-06.301 show a beneficial effect on mucus production and lung inflammation
with systemic treatment. Further experimentation is necessary for a full evaluation
of this drug with titrated doses and local administration. In conclusion, these data
offer optimistic perspectives on the findings of novel compounds for the treatment of
allergic asthma.
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